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ABSTRACT 
Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders 
seen by clinicians in both primary and secondary care. Since publication of the last British 
Society of Gastroenterology guideline in 2007, substantial advances have been made in 
understanding its complex pathophysiology, resulting in its re-classification as a disorder of 
gut-brain interaction, rather than a functional gastrointestinal disorder. Moreover, there has 
been a considerable amount of new evidence published concerning the diagnosis, 
investigation, and management of IBS. The primary aim of this guideline, commissioned by 
the BSG, is to review and summarise the current evidence to inform and guide clinical 
practice, by providing a practical framework for evidence-based management of patients. 
One of the strengths of this guideline is that the recommendations for treatment are based 
upon evidence derived from a comprehensive search of the medical literature, which was 
used to inform an update of a series of trial-based and network meta-analyses assessing the 
efficacy of dietary, pharmacological, and psychological therapies in treating IBS. Specific 
recommendations have been made according to the Grading of Recommendations 
Assessment, Development and Evaluation system, summarising both the strength of the 
recommendations and the overall quality of evidence. Finally, this guideline identifies novel 
treatments that are in development, as well as highlighting areas of unmet need for future 
research. 
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EXECUTIVE SUMMARY OF RECOMMENDATIONS 
Doctor-patient Communication 
• Establishing an effective doctor-patient relationship and a shared understanding is key 
to the management of IBS. Such a relationship can lead to improved quality of life 
and symptoms, reduce health care visits, and enhance adherence to treatment 
(recommendation: strong, quality of evidence: low). 
• Patients with IBS would like increased empathy, support, and information from 
clinicians about the nature of the condition, diagnosis, and symptom management 
options (recommendation: strong, quality of evidence: low). 
Diagnosis, Investigation, and Education 
• The National Institute for Health and Care Excellence guideline definition of IBS 
(abdominal pain or discomfort, in association with altered bowel habit, for at least 6 
months, in the absence of alarm symptoms or signs) is more pragmatic and may be 
more applicable to patients with IBS in primary care than diagnostic criteria derived 
from patients in secondary care, such as the Rome IV criteria (recommendation: 
weak, quality of evidence: low). 
• All patients presenting with symptoms of IBS for the first time in primary care should 
have a full blood count, C-reactive protein or erythrocyte sedimentation rate, coeliac 
serology and, in patients <45 years of age with diarrhoea, a faecal calprotectin to 
exclude inflammatory bowel disease. Local and national guidelines for colorectal and 
ovarian cancer screening should be followed, where indicated (recommendation: 
strong, quality of evidence: moderate). 
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• Clinicians should make a positive diagnosis of IBS based on symptoms, in the 
absence of alarm symptoms or signs, and abnormalities on simple blood and stool 
tests (recommendation: strong, quality of evidence: moderate). 
• Referral to gastroenterology in secondary care is warranted where there is diagnostic 
doubt, in patients with symptoms that are severe, or refractory to first-line treatments, 
or where the individual patient requests a specialist opinion (recommendation: weak, 
quality of evidence: low).  
• There is no role for colonoscopy in IBS, other than in those with alarm symptoms or 
signs, or those with symptoms suggestive of IBS with diarrhoea who have atypical 
features and/or relevant risk factors that increase the likelihood of them having 
microscopic colitis (female sex, age ≥50 years, co-existent autoimmune disease, 
nocturnal or severe, watery, diarrhoea, duration of diarrhoea <12 months, weight loss, 
or use of potential precipitating drugs including non-steroidal anti-inflammatory 
drugs, proton pump inhibitors, etc.) (recommendation: strong, quality of evidence: 
moderate).  
• In those with symptoms suggestive of IBS with diarrhoea, but with atypical features 
such as nocturnal diarrhoea, or a prior cholecystectomy, 23-seleno-25-
homotaurocholic acid scanning or serum 7α-hydroxy-4-cholesten-3-one should be 
considered to exclude bile acid diarrhoea (recommendation: strong, quality of 
evidence: low). 
• In patients with IBS and co-existing symptoms suggestive of a defaecatory disorder or 
faecal incontinence, anorectal physiology tests can be considered, where available, to 
select those who might benefit from biofeedback (recommendation: weak, quality of 
evidence: low).  
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• There is no role for testing for exocrine pancreatic insufficiency, or for hydrogen 
breath testing to rule out small intestinal bacterial overgrowth or carbohydrate 
intolerance, in patients with typical IBS symptoms (recommendation: strong, quality 
of evidence: weak). 
• The diagnosis of IBS, its underlying pathophysiology, and the natural history of the 
condition, including common symptom triggers, should be explained to the patient. 
This should introduce the concept of IBS as a disorder of gut-brain interaction, 
together with a simple account of the gut-brain axis and how this is impacted by diet, 
stress, cognitive, behavioural, and emotional responses to symptoms, and post-
infective changes (recommendation: strong, quality of evidence: weak). 
First-line Treatments 
• All patients with IBS should be advised to take regular exercise (recommendation: 
strong, quality of evidence: weak). 
• First-line dietary advice should be offered to all patients with IBS (recommendation: 
strong, quality of evidence: weak). 
• Food elimination diets based on IgG antibodies are not recommended in patients with 
IBS (recommendation: strong, quality of evidence: moderate).  
• Soluble fibre, such as ispaghula, is an effective treatment for global symptoms and 
abdominal pain in IBS, but insoluble fibre (e.g., wheat bran) should be avoided as it 
may exacerbate symptoms. Soluble fibre should be commenced at a low dose (3-
4g/day) and built up gradually to avoid bloating (recommendation: strong; quality of 
evidence: moderate). 
• A diet low in fermentable oligo-, di-, and monosaccharides and polyols, as a second-
line dietary therapy, is an effective treatment for global symptoms and abdominal pain 
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in IBS, but its implementation should be supervised by a trained dietitian and 
fermentable oligo-, di-, and monosaccharides and polyols should be reintroduced 
according to tolerance (recommendation: weak, quality of evidence very low).  
• A gluten-free diet is not recommended in IBS (recommendation: weak, quality of 
evidence very low).  
• Probiotics, as a group, may be an effective treatment for global symptoms and 
abdominal pain in IBS, but it is not possible to recommend a specific species or strain. 
It is reasonable to advise patients wishing to try probiotics to take them for up to 12 
weeks, and to discontinue them if there is no improvement in symptoms 
(recommendation: weak, quality of evidence: very low). 
• Loperamide may be an effective treatment for diarrhoea in IBS. However, abdominal 
pain, bloating, nausea, and constipation are common, and may limit tolerability. 
Titrating the dose carefully may avoid this (recommendation: strong; quality of 
evidence: very low). 
• Certain antispasmodics may be an effective treatment for global symptoms and 
abdominal pain in IBS. Dry mouth, visual disturbance, and dizziness are common side 
effects (recommendation: weak, quality of evidence: very low). 
• Peppermint oil may be an effective treatment for global symptoms and abdominal 
pain in IBS. Gastro-oesophageal reflux is a common side effect (recommendation: 
weak, quality of evidence: very low). 
• Polyethylene glycol may be an effective treatment for constipation in IBS. Abdominal 
pain is a common side effect (recommendation: weak; quality of evidence: very low). 
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Second-line Treatments 
• Tricyclic antidepressants used as gut-brain neuromodulators are an effective second-
line drug for global symptoms and abdominal pain in IBS. They can be initiated in 
primary or secondary care, but careful explanation as to the rationale for their use is 
required, and patients should be counselled about their side effect profile. They should 
be commenced at a low dose (e.g., 10mg amitriptyline o.d.) and titrated slowly to a 
maximum of 30mg to 50mg o.d. (recommendation: strong, quality of evidence: 
moderate).  
• Selective serotonin reuptake inhibitors used as gut-brain neuromodulators may be an 
effective second-line drug for global symptoms in IBS. As with tricyclic 
antidepressant, they can be initiated in primary or secondary care, but careful 
explanation as to the rationale for their use is required, and patients should be 
counselled about their side effect profile. (recommendation: weak, quality of 
evidence: low).  
• Eluxadoline, a mixed opioid receptor drug, is an efficacious second-line drug for IBS 
with diarrhoea in secondary care. It is contraindicated in patients with prior sphincter 
of Oddi problems or cholecystectomy, alcohol dependence, pancreatitis, or severe 
liver impairment, and lack of availability may limit its use (recommendation: weak, 
quality of evidence: moderate).  
• 5-HT3 receptor antagonists are efficacious second-line drugs for IBS with diarrhoea in 
secondary care. Alosetron and ramosetron are unavailable in many countries; 
ondansetron titrated from a dose of 4mg o.d. to a maximum of 8mg t.i.d. is a 
reasonable alternative. Constipation is the most common side effect. This drug class is 
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likely the most efficacious for IBS with diarrhoea (recommendation: weak, quality of 
evidence: moderate to high).  
• The non-absorbable antibiotic rifaximin is an efficacious second-line drug for IBS 
with diarrhoea in secondary care, although its effect on abdominal pain is limited. The 
drug is licensed for IBS with diarrhoea in the USA but is not available for this 
indication in many countries (recommendation: weak, quality of evidence: moderate).  
• Linaclotide, a guanylate cyclase-C agonist, is an efficacious second-line drug for IBS 
with constipation in secondary care. It is likely to be the most efficacious 
secretagogue available for IBS with constipation, although diarrhoea is a common 
side effect (recommendation: strong, quality of evidence: high).  
• Lubiprostone, a chloride channel activator, is an efficacious second-line drug for IBS 
with constipation in secondary care. This secretagogue is less likely to cause 
diarrhoea than others. However, patients should be warned that nausea is a frequent 
side effect (recommendation: strong, quality of evidence: moderate).  
• Plecanatide, another guanylate cyclase-C agonist, is an efficacious second-line drug 
for IBS with constipation in secondary care. Diarrhoea is a common side effect and is 
no less likely than with linaclotide or tenapanor. Although the drug is licensed for IBS 
with constipation in the USA, it is not yet available for this indication in many 
countries (recommendation: strong, quality of evidence: high).  
• Tenapanor, a sodium-hydrogen exchange inhibitor, is an efficacious second-line drug 
for IBS with constipation in secondary care. Again, diarrhoea is a frequent side effect. 
Although the drug is licensed for IBS with constipation in the USA, it is not yet 
available for this indication in many countries (recommendation: strong, quality of 
evidence: high).  
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• Tegaserod, a 5-HT4 receptor agonist, is an efficacious second-line drug for IBS with 
constipation in secondary care but is unavailable outside the USA. Diarrhoea is a 
common side effect (recommendation: strong, quality of evidence: moderate).  
Psychological Therapies 
• IBS-specific cognitive behavioural therapy may be an efficacious treatment for global 
symptoms in IBS (recommendation: strong, quality of evidence: low). 
• Gut-directed hypnotherapy may be an efficacious treatment for global symptoms in 
IBS (recommendation: strong, quality of evidence: low).  
• Psychological therapies should be considered when symptoms have not improved 
after 12 months of drug treatment. Referral can be made at an earlier stage, if 
accessible locally, and based upon patient preference (recommendation: strong, 
quality of evidence: low). 
Management of Severe or Refractory IBS 
• Severe or refractory IBS symptoms should prompt a review of the diagnosis, with 
consideration of further targeted investigation (recommendation: weak, evidence: 
very low). 
• Severe or refractory IBS should be managed with an integrated multi-disciplinary 
approach (recommendation: weak, evidence: very low). 
• Iatrogenic harms due to opioid prescribing, unnecessary surgery, and unproven 
unregulated diagnostic or therapeutic approaches incentivised by financial or 
reputational gain should be avoided (recommendation: strong, evidence: very low). 
• Use of combination gut-brain neuromodulators, termed augmentation, may be 
considered for more severe symptoms, with vigilance for risks of serotonin syndrome 
(recommendation: weak, evidence: very low). 
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Research 
• Successful completion of large clinical trials will require pragmatic inclusion criteria, 
minimisation of the participant trial burden, and effective recruitment strategies that 
reach into community settings. Virtual (remote access) trial approaches will reduce 
geographical exclusion. 
• A priority-setting partnership would best discern valuable research questions. 
• Some future research themes include, but are not limited to: 
Characterisation of the illness to understand predictors (clinical, genetic, 
psychological, and biological) of outcome and treatment response, 
determinants of refractory illness, and burden of illness (particularly with 
respect to workplace productivity) by conducting large-scale epidemiological 
studies with extended observation. 
Trials of novel treatments, including pharmacological, dietary, and 
behavioural therapies, device-based treatments, and faecal microbiota 
transplantation. There is also a need for development of visceral analgesics. 
Consideration should be given to stratifying randomised controlled trials by 
IBS severity and subtype, burden of extra-intestinal symptoms, and 
psychological co-morbidity.  
A better understanding of treatment combinations to uncover augmentation 
effects between therapies, and to assess the value of multi-disciplinary 
approaches. 
Modulation of pain and psychological responses using pharmacological (e.g., 
serotonin norepinephrine reuptake inhibitors) or behavioural approaches (e.g., 
cognitive behavioural therapy used earlier in the disease course or via digital 
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provision), and comparison of cognitive behavioural therapy with gut-directed 
hypnotherapy. 
Med-tech approaches (web-based, apps, and devices) to behavioural 
modification. 
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PATIENT SUMMARY 
These guidelines have been produced on behalf of the British Society of 
Gastroenterology by a team of specialists, but also with input from patients with irritable 
bowel syndrome (IBS). The guidelines are aimed at healthcare professionals who look after 
patients with IBS. 
IBS is a common condition, which is caused by problems arising between the gut and 
the brain. It consists of symptoms like abdominal pain linked to changes in bowel frequency 
or appearance of stools, and often bloating. Problems in IBS have been found in the nervous 
system supplying the gut, often making it more sensitive. Psychological factors (including 
stress), certain foods, and the micro-organisms (bugs) living in the gut can all play a role in 
triggering symptoms. Occasionally it can start after a gut infection, or antibiotic use, but more 
often there is no clear origin.  
Some patients with IBS learn to manage their symptoms themselves, by changing 
their lifestyle or diet, or managing stress differently. Others, however, will consult their 
primary care physician who can usually make the diagnosis based on the typical symptoms. 
Primary care physicians will carry out some blood tests, including one to rule out coeliac 
disease (an immune reaction to gluten) and, if diarrhoea is present, a stool test to rule out 
inflammation. If there are concerning symptoms, including bleeding from the back passage, 
substantial weight loss, or anaemia, a strong family history of cancer, or the patient is older, 
then the primary care physician will refer to a hospital specialist for further tests. The 
specialist may request a camera test of the large bowel, known as a colonoscopy, or do extra 
tests to look for other causes of diarrhoea or constipation, especially if the patient’s symptoms 
are less typical of IBS. 
Regular exercise, making some simple dietary changes, and adopting healthy eating 
patterns will help many patients. Some patients find reducing dietary fibre improves 
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symptoms, whilst others may find that a soluble fibre supplement helps. Referral to a 
dietician can be helpful if these first-line approaches to diet do not help. Taking supplements 
of probiotics (often referred to as “friendly bacteria”) may also help, but these can be 
expensive.  
Some patients may require different medications, depending on their main symptom. 
Some of these can be obtained over the counter, but others need to be prescribed by a doctor. 
This guideline has reviewed the evidence for which medications work, and the possible 
harms they may cause. We have only recommended medications with good evidence that 
they are effective and have recommended against tests or treatments where the evidence is 
that they do not help, are harmful, or where there is not enough evidence. Some medications 
have most of their effect on the gut itself, others work both at the level of the gut and the 
brain (called “neuromodulators” as they help to reduce nerve sensitivity). Some drugs that 
have good evidence are unfortunately not available, or are too expensive, in some countries. 
There is good evidence that psychological treatments directed against IBS symptoms, 
especially cognitive behavioural therapy, and hypnotherapy, are helpful for many patients’ 
symptoms, but unfortunately these are not always readily accessible. Work is being done to 
improve access to these.  
Very severe symptoms that do not respond to some of the above treatments are rare. 
However, patients whose symptoms do not improve may be left feeling desperate, and 
therefore vulnerable to approaches which are not proven, expensive, or high risk. It is 
recommended that patients in this position are supported by a multi-disciplinary specialist 
team to help reduce harms, such as unwarranted tests or operations, or harmful drugs. 
Although much progress has been made in understanding and treating IBS, there are 
still many things we do not know about the condition, and there are lots of active areas for 
research, and therapies that need to be explored. We hope this guideline will also help to 
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highlight and prioritise these areas. 




Since the last British Society of Gastroenterology (BSG) guideline on IBS was 
published in 2007, [1] there has been a considerable amount of new evidence pertaining to 
the pathophysiology, diagnosis, investigation, and management of the condition. 
Furthermore, the gold standard symptom-based diagnostic criteria for IBS, the Rome criteria, 
are now in their fourth iteration. [2] The primary aim of this guideline, commissioned by the 
BSG, is to update the 2007 guideline, considering all these developments, but with a 
particular focus on treatment of the condition. The overarching intention is to provide a 
guideline that is practical to use and an authoritative framework for current, state of the art, 
evidence-based clinical practice. 
 
Methodology 
In line with the AGREE (Appraisal of Guidelines for REsearch & Evaluation) 
guideline development protocol, [3] a diverse multi-disciplinary working group of clinicians 
and academics was convened from across the interface of primary, secondary, and tertiary 
care, as well as psychology and dietetics. To ensure a patient-centred approach at the outset, 
the proposal was reviewed by the IBS network, Guts UK, and by four patients with IBS who 
were invited to join the working group. 
Each section lead performed a comprehensive literature search, except for the section 
dealing with treatment, which was informed by a systematic review of the literature, the 
methodology for which is reported within that section. Eligible studies were graded according 
to the Oxford Centre for Evidence Based Medicine. [4] The Grading of Recommendations 
Assessment, Development and Evaluation system was used to evaluate the strength of the 
recommendations and the overall quality of evidence. [5] Thereafter, all members of the 
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working group reviewed and approved the entire guideline. 
 
Conflicts of Interest 
All members of the working group were asked to complete conflict of interest 
declarations. These are available as a supplementary on-line table. 
 
Scheduled Review 
We would suggest these guidelines are reviewed and updated every 4 years. 
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CLASSIFICATION AND DIAGNOSTIC CRITERIA 
In the absence of any biomarker being available for IBS, the condition is diagnosed 
using a positive approach, based on the clinical history. Symptom-based diagnostic criteria 
have been developed to facilitate this, according to a specific pattern of gastrointestinal 
symptoms reported by the patient, with recourse to limited investigations. These criteria were 
developed by the Rome Foundation, and the most recent iteration, Rome IV, were published 
in 2016 (Table 1). [2] These define IBS as the presence of abdominal pain, related to 
defaecation, associated with a change in stool frequency and/or stool form. Patients are sub-
grouped according to their predominant stool pattern into IBS with diarrhoea (IBS-D), IBS 
with constipation (IBS-C), IBS with mixed bowel habits (IBS-M), or IBS unclassified (IBS-
U), to direct therapy. The presence of abdominal pain at the required frequency distinguishes 
IBS from the other functional bowel disorders, which consist of functional constipation, 
functional diarrhoea, and functional abdominal bloating or distension. [2] However, there is 
some degree of overlap and fluctuation between IBS and these other disorders. [6, 7] The 
Rome IV process also redefined IBS as a disorder of gut-brain interaction, in recognition of 
the complex interplay of biological, psychological, and social factors underpinning the 
condition. 
 The Rome IV criteria made some important changes, [2] compared with their 
predecessor, Rome III. [8] First, abdominal “discomfort” was removed from the definition, as 
this was felt to be a vague term that was not understandable in some languages. [9] Second, 
the minimum required frequency of abdominal pain was increased from at least 3 days per 
month, to at least 1 day per week. This change reflected the findings of a normative survey 
showing that adopting a higher threshold for the frequency of abdominal pain required to 
meet criteria for IBS would lead to fewer healthy people in the general population being 
misclassified as having IBS, [9] and therefore risk being “medicalised”, and having to take 
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drugs for the condition. This feature makes the Rome IV criteria potentially more specific 
than Rome III. Third, it was no longer necessary for abdominal pain to be relieved by 
defaecation. Instead, it should be “related to defaecation”, acknowledging that some patients 
with IBS report that their pain worsens following a bowel movement. [2] 
This more restrictive nature of the Rome IV criteria calls into question whether they 
should be used to diagnose IBS in clinical practice, and a more pragmatic definition of the 
symptoms that constitute IBS may be preferred. The National Institute for Health and Care 
Excellence (NICE) guideline for the management of IBS in primary care recommends a 
broader, more pragmatic, definition of IBS, [10] focusing on abdominal pain or discomfort 
associated with altered stool frequency or stool form for at least 6 months, in the absence of 
alarm symptoms or signs, and acknowledging that co-existent bloating, lethargy, nausea, 
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EPIDEMIOLOGY 
Symptoms compatible with IBS are extremely common in the general population at 
any particular point in time, [11] and experienced on a continuum, from what may be fleeting 
and part of normal health, to a disease process, requiring medical input. In the latter instance, 
IBS is chronic, with fluctuating symptoms, in the majority of patients. [12] However, few 
epidemiological studies have conducted follow-up beyond 12 months, and most drug trials 
take place over 12 weeks, meaning that factors predicting continuation or resolution of 
symptoms is unclear. The condition impacts on social functioning, quality of life, [13] and 
ability to work, with one-in-four patients reporting sickness related absences from work, and 
up to 80% presenteeism in the workplace. [14] The annual direct and indirect costs related to 
IBS are estimated to be up to €8 billion in Europe, [15] ¥123 billion in China, [16] and in 
excess of $10 billion in the USA. [17]  
Prior to the publication of the Rome IV criteria in 2016, two systematic reviews and 
meta-analyses quantified the global prevalence of IBS. The first of these, published in 2012, 
included data from 260,960 individuals across 81 different countries and calculated a pooled 
global prevalence of IBS of 11%, irrespective of definition used. [11] Prevalence varied 
widely between countries, and according to the criteria used to define IBS, ranging from 
1.1% in one Iranian study that used the Rome III criteria, to 45% in a study from Pakistan 
that used Rome II. The second systematic review and meta-analysis, from 2017 and 
conducted by the Rome Foundation, found similar variability in the prevalence of IBS, which 
ranged from 1.1% in France and Iran, to 35.5% in Mexico, and with a pooled global 
prevalence of 8.8%. [18] In both meta-analyses, heterogeneity between studies was 
substantial, presumably relating to differences in methodology, demographic characteristics 
of participants, cultural issues, or a combination of these factors.  
Due to the uncertainty surrounding pooled estimates of global prevalence, and the 
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apparent variation in prevalence between countries in separate studies, a subsequent Rome 
Foundation global survey has quantified the prevalence of IBS, among 73,000 adults in 33 
different countries simultaneously, using both the Rome III and IV criteria. [19] The 
worldwide prevalence of IBS was 4.1% using the Rome IV criteria, compared with 10.1% 
with Rome III. An update of the systematic review and meta-analysis from 2012 
incorporating the results of this global survey, [20] demonstrated a pooled prevalence of IBS 
according to the Rome III criteria of 9.2%, in 53 studies recruiting 400,000 participants from 
38 countries, compared with 3.8% using Rome IV, based on findings from six studies 
including over 80,000 individuals from 34 countries. With respect to sex, the prevalence of 
IBS was modestly, but significantly, higher in women than men in this meta-analysis (odds 
ratio 1.46; 95% confidence interval (CI) 1.33-1.59) based on 30 studies using the Rome III 
criteria. [20] The Rome Foundation global survey also reported a substantially higher pooled 
prevalence of IBS among women, compared with men, using the Rome IV criteria (odds ratio 
1.8; 95% CI 1.7-2.0). [19] Prevalence of IBS decreased modestly with increasing age, 
irrespective of diagnostic criteria, in a prior meta-analysis, although this trend was not 
statistically significant. [11] Similarly, in the Rome Foundation global survey, prevalence of 
both Rome III and Rome IV IBS decreased with age and was highest among adults aged 18-
39 years. [19] 
The fall in prevalence in IBS that results from the changes made in moving from the 
Rome III to Rome IV criteria is noteworthy, reflecting the more restrictive nature of the latter. 
This has important clinical implications because, although as intended, the criteria are now 
more specific for diagnosing IBS, [21] up to 50% of patients who believe they have IBS will 
no longer meet criteria for the condition. Instead, they will be diagnosed as having another 
functional bowel disorder, [22, 23] such as functional diarrhoea, functional constipation, or 
functional abdominal bloating or distension. Moreover, there may be an impact on treatment 
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trials in IBS, and the interpretation of results, because patient populations recruited using the 
Rome IV criteria will differ from those recruited using Rome III, and may have more severe 
symptoms and higher degrees of psychological co-morbidity. [23, 24] Moving from Rome III 
to Rome IV IBS may therefore reduce the likelihood of novel pharmacological therapies 
demonstrating efficacy in future randomised controlled trials (RCTs), due to the spectrum of 
symptom severity, or may mean that trials need to be considerably larger, and therefore more 
expensive to conduct, to show a beneficial effect.  
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PATHOPHYSIOLOGY 
The pathophysiology of IBS is complex and remains poorly understood. [2] Genetics, 
and epigenetic changes, infection, and early adverse life events may predispose an individual 
to developing IBS, [25-28] and chronic stress, psychological symptoms, negative beliefs 
about symptoms and illness, and maladaptive coping mechanisms can increase the frequency 
and severity of symptoms. [29, 30] For some patients with IBS, psychological co-morbidity 
or distress may be a consequence, rather than a cause, of the severity and frequency of 
symptoms experienced. [31] IBS is a disorder of altered bidirectional communication 
between the gut and brain (via the gut-brain axis), and has a biopsychosocial aetiology. [32] 
As a result, it has been re-termed a disorder of gut-brain interaction. [32] An exhaustive 
discussion of the involved pathophysiological mechanisms is beyond the scope of this 
guideline, but the best accepted of these are summarised below.  
 
Central Nervous System and Autonomic Nervous System Modulation 
  Symptoms are generated by interoceptive signals from the gut, and memories of such 
signals, and are modulated by emotional (anxiety, depression), cognitive (attention, beliefs, 
and expectation), and motivational factors. [33] Altered activation of brain regions 
responsible for cognitive processing and emotional and autonomic responses to visceral and 
somatic stimuli are seen in IBS, consistent with visceral hypersensitivity, hypervigilance, and 
symptom-related anxiety. [34] Some patients with IBS have compromised central inhibitory 
regulation of visceral and somatic stimuli. [35] Modulating activity of the brain regions 
responsible for visceral pain using various therapies has been shown to improve IBS 
symptomatology. [36-38] 
The autonomic nervous system mediates communication between the gut and brain. 
In IBS, a reduction in parasympathetic activity and an increase in sympathetic nervous 
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system activity is frequently observed. [39] Reduced vagal tone may be caused by stress, and 
impacts not only on gut motility and sensitivity, but also peripheral inflammation and gut 
permeability. [40] Conversely, the vagus nerve may sense the gut microenvironment 
indirectly and transfer this information to the brain.  
 
Altered Visceral Perception 
Between 20% and 60% of patients with IBS have enhanced visceral perception to 
various physiological stimuli (e.g., mechanical or electrical). [41] Hypersensitivity to 
mechanical distension of the gut is reported by more patients with IBS-D than IBS-C. 
However, studies do not distinguish between affective, cognitive, and true peripheral, versus 
central, mechanisms of visceral hypersensitivity. A study conducted in separate patient 
cohorts from Sweden, Belgium, and the USA reported that visceral sensitivity correlated 
positively with symptom severity, even after adjustment for the tendency to report symptoms 
or psychological co-morbidity. [42] Approximately 20% of patients with IBS are viscerally 
hyposensitive or insensitive to mechanical distension, more commonly those with IBS-C than 
IBS-D, with one study suggesting that the degree of insensitivity correlated with abdominal 
distension (i.e., a true physical increase in abdominal girth). [43] 
 
Transit and Motility  
Colonic transit is abnormal in only 10% to 20% of patients with IBS-C and IBS-M, 
and 25% to 45% of patients with IBS-D. [44, 45] Similar observations are seen for oro-caecal 
transit. [46, 47] However, patients with normal transit can still have abnormal fasting and 
postprandial motility. [48] Patients with IBS-C display reduced motility, fewer high 
amplitude propagating contractions of the colon, and delayed transit, whereas those with IBS-
D have increased motility, more high amplitude propagating contractions, and accelerated 
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transit. [1] Colonic transit time correlates inversely with stool consistency and, to a lesser 
extent, with stool frequency. [45] However, symptoms of abdominal pain, bloating, and 
flatulence correlate poorly, or not at all, with colonic transit, [45, 46] whereas abdominal 
distension (the physical increase in abdominal girth, rather than the sensation of bloating) 
correlates with oro-caecal and colonic transit times, and inversely with stool consistency. [46] 
High amplitude propagating contractions in IBS-D patients are associated with abdominal 
pain. [1] Changes in gastrointestinal motility may be influenced by alterations in serotonin (5-
hydroxytryptamine (5-HT)) metabolism, [49] with high levels reported in patients with IBS-
D, and low levels in IBS-C. [50] 
 
Immune Regulation, Inflammation, and Epithelial Permeability 
Low-grade mucosal inflammation may arise from a compromised epithelial barrier, 
dysbiosis, or altered stress levels, but also impaired epithelial barrier function from an 
aberrant stress and immune response, and/or dysbiosis. It can be linked to a previous episode 
of infectious gastroenteritis induced by bacteria, parasites, or viruses, referred to as post-
infection IBS (PI-IBS). [51] Increased numbers of mast cells, particularly in the descending 
colon and recto-sigmoid region, [52, 53] but also in the small intestine, [54] is the most 
consistent histological finding in IBS. Mast cell hyperplasia is more common in IBS-D and 
PI-IBS. [52, 55] The severity and frequency of abdominal pain correlates with the presence of 
activated mast cells in close proximity to nerve endings in the gut mucosa in some studies, 
[56] but in others mast cell proliferation associates with a reduction, [57] or no change, [58] 
in visceral sensitivity. IL-10mRNA expression and protein levels are consistently reduced in 
the mucosa and/or peripheral circulation, in patients with IBS-D and PI-IBS, and associate 
with co-morbid anxiety or depression. [59] There is lack of consensus on whether numbers of 
T cells and levels of cytokines in the peripheral circulation of patients with IBS are abnormal. 
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[52, 53] 
Increased permeability in patients with PI-IBS and IBS-D correlates with visceral 
sensitivity, [60, 61] and symptom severity. [62, 63] However, findings in patients with IBS-C 
are inconsistent. [64, 65] The expression and levels of the tight junction protein zonula 
occludens are significantly reduced in IBS-D, and associated with mast cell activation and 
symptoms. [66] Confocal laser endomicroscopy studies suggest exposure to certain food 
antigens can disrupt the epithelial barrier in approximately 50% of patients with IBS. [67, 68] 
Removal of the reacting antigen from the diet improved symptoms significantly. [67]  
 
The Microbiome 
Strong evidence supports a role for bacterial, viral, or parasitic infections triggering 
IBS. [51] Antibiotic usage may also associate with either the development, [69] or 
improvement, [70] of IBS symptoms. Moreover, changes in the gut microbiome can modify 
gastrointestinal motility, visceral sensation, intestinal permeability, stool consistency, and 
visceral sensitivity. [71, 72] In a mouse model, bacterial infection led to an increase in 
intestinal permeability, which appeared to allow previously tolerated food antigens to activate 
a localised host immune response in the gastrointestinal tract, via IgE, leading to histamine 
release, altered motility, and visceral hypersensitivity. [73] There is no conclusive evidence 
for a specific IBS gut microbiome profile. [74, 75] However, an integrated longitudinal multi-
omics analysis of the gut microbiome, metabolome, host epigenome, and transcriptome, in 
the context of host symptoms and physiology in patients with IBS-D and IBS-C, identified 
subtype-specific and symptom-related variations in microbial composition and function. [76] 
It remains unclear whether such microbial changes are secondary and relate to other factors 
including diet, drugs, altered physiology, including gastrointestinal transit, or gastrointestinal 
water content. 
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Genetics and Epigenetics 
Familial clustering of IBS may be attributed to both genetic and shared environmental 
factors. [77, 78] In addition, numerous genetic single nucleotide polymorphisms have been 
described in association with symptom phenotypes, regulation of neurotransmission, barrier 
function, inflammatory mediators, ion channels, and bile acid metabolism in IBS. [77, 78] 
However, a meta-analysis of genes associated with inflammatory mediators found no 
significant associations for most genes assessed. [79] There is some evidence for epigenetic 
changes in IBS, including alterations in DNA methylation, and various miRNAs appear to be 
associated with increased visceral sensitivity and permeability. [80] 
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PRESENTATION OF IBS, DIAGNOSIS, AND MANAGEMENT IN PRIMARY CARE 
Overview 
Patients may have IBS-type symptoms for many years without presenting to medical 
care, often self-managing their symptoms without medical input, and some may never 
consult. Nevertheless, lower gastrointestinal symptoms frequently prompt people to present 
to primary care, [81] accounting for approximately 1 in 12 of all consultations. [82] 
Functional gastrointestinal disorders, such as IBS, are by far the most common diagnosis, but 
symptoms can be difficult to assess and the possibility of colorectal cancer or inflammatory 
bowel disease (IBD) may create diagnostic uncertainty for clinicians, and anxiety for patients. 
[83]  
Primary care physicians are the first point of contact and provide the diagnosis and 
medical care for most people with IBS. Management guidelines encourage primary care 
physicians to make a positive diagnosis of IBS, based on symptoms, in the absence of alarm 
symptoms or signs that warrant referral to exclude colorectal cancer (Table 2), [84] or 
abnormalities on simple investigations. [10] However, persistent abdominal bloating or 
distension in female patients should prompt consideration of CA-125 and pelvic ultrasound to 
exclude ovarian cancer. [85] Primary care physicians provide the majority of long-term 
medical care for people with IBS, referring only a minority of patients to specialist clinics. 
[86] Compared with hospital settings, primary care physicians can, and should, aim to build a 
longer-term relationship with patients, harnessing this to develop a shared understanding of 
their IBS in the context of their other medical conditions, concerns, priorities, and impact on 
their lives. [87, 88] This can assist in providing appropriate tailored education, advice and 
reassurance, shared decision-making, and management plans, and be facilitated by an 
ongoing supportive doctor-patient relationship and prioritisation of continuity of care. 
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Doctor-patient Communication and Patient Perspectives in Primary Care 
Establishing an effective doctor-patient relationship and a shared understanding is key 
to the successful diagnosis and management of chronic conditions such as IBS. [89, 90] 
Reports from patients with IBS confirm that they would like increased empathy, support, and 
information about the nature of the condition from primary care physicians, and options for 
symptom management. [87] They often feel their symptoms are dismissed or trivialised, 
describe the diagnostic process as confusing, or invasive, and the often-lengthy search for 
efficacious treatments as frustrating. [87, 89, 91-95] 
Patients often seek information and support from multiple sources, including internet 
web forums, [96] and may receive conflicting, or incorrect, advice. Clinicians should aim to 
gain a better understanding of patients’ ideas, concerns, and expectations of diagnosis and 
management. Multiple factors influence both the patient’s decision to consult their doctor 
with IBS, and their ability and willingness to self-manage symptoms and engage with 
treatment. These factors include the impact on their own and their family’s lives, social and 
psychological factors, employment, co-morbidities, and health beliefs. All should be 
considered and acknowledged for successful diagnosis and management of IBS in primary 
care, and good doctor-patient communication generally. 
 
Presentation of IBS to Primary Care 
Primary care physicians must assess and manage undifferentiated disease, multiple 
co-morbidities, health anxieties, and hidden agendas in brief consultations. Multiple factors, 
described above, influence patients’ decisions to consult. Concerns about serious illness, 
advice or pressure from friends or relatives, life events, and underlying health beliefs can all 
drive healthcare-seeking behaviour. Understanding reasons for presenting at a particular point 
in time, especially if symptoms have been present for many years, is important in determining 
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the most appropriate management strategy.  
Primary care physicians’ key skills, especially in relation to chronic disorders such as 
IBS, are to make a positive diagnosis, including providing a simple explanation of the 
pathophysiology underlying the symptoms, clarifying the patient’s main concerns, and 
managing current symptoms in the wider context of the patient’s life. The doctor’s 
relationship with the patient, continuity of care, empathy, including acknowledgement of the 
impact of symptoms on daily life, a shared understanding of IBS, and shared decision-making 
can assist in providing appropriate education, signposting to reputable online information or 
peer support, reassurance, advice, and management options.  
 
Diagnosis of IBS in Primary Care 
The key to diagnosis starts with skilled, targeted history taking and examination, 
considering the patient’s medical history and life circumstances. The Rome diagnostic criteria 
are based on specific symptoms of a defined duration and frequency, [2] which have been 
derived predominantly from secondary care patients, and are rarely used in primary care. [97] 
Their applicability to clinical practice has been challenged as unnecessarily restrictive, [98] 
and only a minority of people diagnosed with IBS in primary care fulfil them. [99] 
This restrictive diagnostic approach to IBS may be unhelpful and overly complicated 
in this setting, where fundamentals of clinical management are common across all these 
functional gastrointestinal disorders. Applying rigid criteria potentially leaves many patients 
with troublesome impactful symptoms without a clear diagnosis, increasing uncertainty, and 
leading to issues with providing appropriate advice and management options. The NICE 
guideline definition of IBS is therefore preferable. [10]  
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Investigation in Primary Care 
A positive diagnosis of IBS can be made on the basis of on-going characteristic 
symptoms, after assessing for alarm symptoms or signs, and undertaking relevant blood test 
results, including full blood count (FBC), C-reactive protein (CRP) or erythrocyte 
sedimentation rate (ESR), and serological tests for coeliac disease. [10] The chance of 
identifying organic disease on the basis of checking FBC, CRP, and ESR in suspected IBS is 
low, [100] but the prevalence of abnormal serological testing for coeliac disease is almost 
three times higher in people with suspected IBS than people without symptoms of IBS, 
irrespective of predominant stool pattern. [101] If all these blood tests are normal, other 
investigations should be minimised. Abdominal and digital rectal examination can help 
exclude other diagnoses, and may confirm the consistency of stool, including rectal 
impaction, or identify dyssynergic defaecation (paradoxical contraction on rectal examination 
during straining) or low rectal masses. [102] An abdominal X-ray can be considered to rule 
out faecal loading if constipation is the predominant symptom. 
The non-invasive marker of intestinal inflammation faecal calprotectin has enabled 
risk stratification to prioritise access to investigations to exclude IBD in patients with chronic 
diarrhoea, reducing unnecessary investigations and referrals from primary to secondary care. 
[103] However, calprotectin is not specific to IBD and can be elevated in older age groups 
(age ≥45 years), obesity, infection, malignancy, or by medications, such as proton pump 
inhibitors (PPIs) or non-steroidal anti-inflammatory drugs (NSAIDs). Local laboratory values 
vary but, generally, a faecal calprotectin of <100mcg/g can be considered normal, 100-
249mcg/g is borderline and should be repeated, with subsequent referral if persistently 
elevated, and ≥250mcg/g requires urgent referral to secondary care to exclude IBD. [103] 
Faecal occult blood or faecal immunochemical testing are not used routinely for assessing 
patients with possible IBS in primary care, although they are recommended in current 
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guidelines for colorectal cancer screening. [104] Local and national guidelines for colorectal 
and ovarian cancer screening should be followed, where indicated. Once a diagnosis of IBS 
has been made, the primary care physician should endeavour to follow-up the patient within 
the next 2 months to ensure symptoms are not getting progressively worse, which may be 
indicative of a more sinister underlying disease process.   
 
When to Refer Patients to Secondary Care 
Most patients with IBS are diagnosed and managed by primary care physicians in 
community settings and are never referred to secondary care, even if they have on-going 
troublesome symptoms. [82] In a primary care study of patients with refractory IBS, only 
10% had ever had a secondary care referral. [86] Reasons for seeking a secondary care 
opinion include: uncertainty about the diagnosis or alarm symptoms or signs; on-going 
refractory symptoms that have not improved despite lifestyle changes (including diet, and 
trials of medication), necessitating initiation of therapies that are unavailable in primary care; 
or patient request for a specialist opinion. 
 
Recommendations 
• Establishing an effective doctor-patient relationship and a shared understanding is key 
to the management of IBS. Such a relationship can lead to improved quality of life 
and symptoms, reduce health care visits, and enhance adherence to treatment 
(recommendation: strong, quality of evidence: low). 
• Patients with IBS would like increased empathy, support, and information from 
clinicians about the nature of the condition, diagnosis, and symptom management 
options (recommendation: strong, quality of evidence: low). 
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• The National Institute for Health and Care Excellence guideline definition of IBS 
(abdominal pain or discomfort, in association with altered bowel habit, for at least 6 
months, in the absence of alarm symptoms or signs) is more pragmatic and may be 
more applicable to patients with IBS in primary care than diagnostic criteria derived 
from patients in secondary care, such as the Rome IV criteria (recommendation: 
weak, quality of evidence: low). 
• All patients presenting with symptoms of IBS for the first time in primary care should 
have a full blood count, C-reactive protein or erythrocyte sedimentation rate, coeliac 
serology and, in patients <45 years of age with diarrhoea, a faecal calprotectin to 
exclude inflammatory bowel disease. Local and national guidelines for colorectal and 
ovarian cancer screening should be followed, where indicated (recommendation: 
strong, quality of evidence: moderate). 
• Clinicians should make a positive diagnosis of IBS based on symptoms, in the 
absence of alarm symptoms or signs, and abnormalities on simple blood and stool 
tests (recommendation: strong, quality of evidence: moderate). 
• Referral to gastroenterology in secondary care is warranted where there is diagnostic 
doubt, in patients with symptoms that are severe, or refractory to first-line treatments, 
or where the individual patient requests a specialist opinion (recommendation: weak, 
quality of evidence: low).   
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CLINICAL HISTORY AND INVESTIGATION IN SECONDARY CARE  
The First Consultation in Secondary Care  
IBS is one of the most common disorders that gastroenterologists deal with, 
accounting for at least 10% of consultations in the outpatient clinic. [105] Patients presenting 
to secondary care often attend the consultation with the hope that the specialist can diagnose 
an organic disease that has been missed in primary care. This may be because a diagnosis of 
IBS is stigmatised, [106] or considered, erroneously, as a purely psychological disorder, [107] 
or due to unexpressed concerns of a missed sinister cause of their symptoms. These aspects 
should all be considered by the secondary care clinician when managing patient expectations 
and selecting appropriate investigations. [107] It is equally important to build rapport and to 
build trust in the doctor-patient relationship in secondary care by adopting the principles of 
empathic listening to optimise the interaction. [108] Evidence suggests that 2 minutes of 
active listening at the beginning of a consultation gives the patient the feeling of having being 
listened to, [109] and therefore having confidence in subsequent decisions around their care. 
An empathic approach can improve quality of life and symptoms, [110] reduce health care 
visits, and enhance adherence to treatment. [108, 111] The principles of history taking are 
similar to those in primary care. It is useful to screen for potential symptom triggers, 
including previous acute enteric infection, present in approximately 10% of people with IBS, 
[112] antibiotics, or psychological stress. This demonstrates to the patient not only that the 
clinician is interested in understanding their disorder, but also helps the patient’s 
understanding of the possible underlying aetiology and validates the diagnosis.  
It is important to start the consultation by asking when the patient’s symptoms started 
(Figure 1). A detailed history should confirm presence of the cardinal symptoms of IBS. 
These include abdominal pain and altered bowel habit (abnormal stool frequency and/or 
consistency) and, in particular, the relationship between the two, remembering that the 
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location of pain can be in the upper or lower abdomen. Importantly, the clinician needs to 
assess whether the patient recognises that there is a link between the pain and the alteration in 
bowel habit. Thus, pain can be relieved or exacerbated by defaecation, or associate 
temporally with changes in bowel habit (e.g., the pain is present when the individual is more 
constipated or has worsening diarrhoea). Predominant stool pattern, on days when the 
patient’s stools are abnormal, should be assessed using the Bristol stool chart. [113] Attention 
should also be paid to other gastrointestinal symptoms. The presence of bloating is not 
required to fulfil the Rome IV criteria but, if present, is highly suggestive of IBS, and is often 
accompanied by visible abdominal distension. [114] Although the Rome IV criteria are the 
gold standard to define IBS for research purposes, they are probably overly restrictive for use, 
even in secondary care, and a pragmatic definition in line with that used in the NICE 
guideline, [10] and outlined above, should be preferred. 
Co-existent early satiety, postprandial fullness, epigastric pain, nausea, or heartburn 
are common, as functional dyspepsia and gastro-oesophageal reflux frequently overlap with 
IBS. [115-117] Extra-intestinal symptoms, such as back pain, bladder and gynaecological 
symptoms, and insomnia are frequent, as is the presence of other functional somatic 
disorders, such as fibromyalgia, tension headache, or chronic fatigue. [118] Common mental 
disorders, and somatoform-type behaviour, often co-exist. [119, 120] A patient with more 
severe IBS may volunteer a history of abuse, or respond to a cue when told that “some people 
report abuse as a possible cause…”. It is, therefore, important to consider all these factors 
when assessing a patient with a possible diagnosis of IBS during the initial consultation, as 
not only do they add diagnostic value, but they also predict the degree of functional limitation 
of the condition, reduction in quality of life, and healthcare utilisation. [117] This may 
prevent presentation to multiple other specialities, and avoid iatrogenic harm from 
unnecessary interventions. [121] Objective evidence of weight loss is also important to assess 
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and document. Other relevant items in the clinical history include previous surgical 
interventions, and a family history of gastrointestinal cancer, IBD, coeliac disease, or IBS. 
Finally, attention should be taken to exclude gastrointestinal symptoms related to a change in 
diet, drugs that can alter gut motility, such as psychotropic agents or opioids, or alcohol 
excess. 
 
Investigations in Secondary Care 
In a patient with normal investigations from primary care on referral, exhibiting 
typical symptoms, and in the absence of alarm symptoms or signs, or atypical features, the 
diagnosis of IBS is secure (Figure 1). A validation study of the Rome IV criteria in secondary 
care demonstrated this was particularly the case for IBS-C and IBS-M. [21] Patients meeting 
these criteria were 21 times more likely to have IBS-C than to not have IBS-C, and 11 times 
more likely to have IBS-M than to not have IBS-M after limited diagnostic work-up. The 
clinician should, therefore, appear confident and, after clinical assessment is complete, 
communicate a positive diagnosis of IBS based on symptoms. In those with alarm symptoms 
or signs, urgent referral for colonoscopy or radiological evaluation of the colon is required, 
[10] although the diagnostic performance of alarm symptoms or signs is modest, [122] and up 
to 80% of patients with IBS in primary and secondary care will report at least one alarm 
symptom. [123] In those with atypical features, such as nocturnal diarrhoea or abdominal 
pain, or features of obstructive defaecation, further limited investigation may be required to 
exclude important mimics. [124] These include microscopic colitis or primary, or idiopathic, 
bile acid diarrhoea (BAD) in those with suspected IBS-D, and dyssynergic defaecation and 
other defaecatory disorders in those with suspected IBS-C. 
The yield of colonoscopy in patients with IBS is extremely low, [125] and there is no 
evidence of reassurance being derived by patients from a normal examination. [126] 
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However, colonoscopy to exclude microscopic colitis should be considered in patients with 
diarrhoea. Factors that should alert the clinician to the possibility of microscopic colitis 
include female sex, age ≥50 years, co-existent autoimmune disease, nocturnal or severe, 
watery, diarrhoea, duration of diarrhoea <12 months, weight loss, or use of potential 
precipitating drugs including NSAIDs, PPIs, selective serotonin reuptake inhibitors (SSRIs), 
or statins. [127-129]  
In primary BAD, bile acids enter the colon, enhancing mucosal permeability, inducing 
water and electrolyte secretion, and accelerating colonic transit. The condition is diagnosed 
via 23-seleno-25-homotaurocholic acid (SeHCAT) scanning, although this may be 
unavailable in some countries. [130] A serum 7α-hydroxy-4-cholesten-3-one is a reasonable 
alternative. The current BSG guideline for the investigation of chronic diarrhoea does not 
recommend a therapeutic trial of a bile acid sequestrant as a diagnostic test for BAD, [131] 
because a lack of response does not exclude the condition. [132] Symptoms of BAD can 
mimic IBS-D, with between one-in-three and one-in-four patients with suspected IBS-D 
having an abnormal SeHCAT retention, [133, 134] and response rates to a bile acid 
sequestrant are higher at retentions of <10% or <5%. [135] Predictors of primary BAD are 
lacking, other than higher body mass index, [133] but if nocturnal or severe diarrhoea is 
present the diagnosis should be considered. BAD should also be suspected in patients with 
symptoms suggestive of IBS-D with prior cholecystectomy. 
Symptoms suggestive of a defaecatory disorder include straining at stool, a sensation 
of incomplete, or blocked, evacuation, and use of digital manoeuvres to facilitate defaecation. 
However, these symptoms are common in patients with IBS-C, as well as in those with 
functional constipation, and whether they arise due to different pathophysiological 
mechanisms in the two disorders is unclear. [136, 137] In the presence of these symptoms, or 
of faecal incontinence, physiological testing could be considered, where available, to 
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facilitate selection of patients most likely to benefit from targeted pelvic floor biofeedback 
therapy to improve anorectal function. [138] Particular caution should be given to 
considering surgical correction of anorectal anatomic alterations in patients with typical 
symptoms of IBS-C, as no prospective studies have demonstrated surgery improves 
symptoms. [139] Likewise, abdominal pain is considered a relative contraindication to 
surgical correction of refractory slow transit constipation. [139] 
Some investigators have reported a high prevalence of exocrine pancreatic 
insufficiency (EPI) in patients with suspected IBS, [140] although other studies have not 
confirmed this. [141] The current BSG guideline for the investigation of chronic diarrhoea 
only recommends screening patients for EPI, via faecal elastase, if features consistent with fat 
malabsorption are present. [131] Similarly, testing patients with suspected IBS-D for EPI is 
not recommended, unless steatorrhoea is reported. Finally, there is no role for hydrogen 
breath testing to exclude lactose intolerance or small intestinal bacterial overgrowth in 
patients with IBS, particularly as these tests may be falsely positive in patients with IBS, due 
to rapid transit. [142] Studies using small intestinal aspiration, considered the gold standard 
for diagnosing small intestinal bacterial overgrowth, have not demonstrated an increased 
prevalence of the condition in suspected IBS, [143] and the lactulose breath test correlates 
poorly with small intestinal aspiration. [144] In addition, despite this being the rationale for 
use of non-absorbable antibiotics in IBS, [70] a positive breath test result does not predict 
response to treatment. [145] Similarly, variants in the sucrase-isomaltase gene have been 
reported to be associated with an increased risk of IBS, [146] and some investigators have 
reported evidence of sucrase-isomaltase deficiency on small intestinal biopsy in patients with 
suspected IBS, [147] but at present there is insufficient evidence for consideration of routine 
testing.  
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Communicating a Positive Diagnosis and Management Plan in Secondary Care 
A diagnosis of IBS needs to be communicated clearly to the patient using simple 
words and explanations. There is evidence that patient education about the condition can lead 
to an improvement in symptoms. [148] It should be underlined that IBS is a chronic disorder, 
with recurrent fluctuating symptoms triggered by stress, intercurrent illnesses, drugs, and 
often the act of eating. IBS is not associated with an increased risk of cancer or mortality, 
[149] but affects quality of life to the same degree as organic gastrointestinal diseases, such 
as IBD. [13] The main pathophysiological aspect is related to visceral hypersensitivity, which 
is also the principal target of many current treatments. Therefore, explaining IBS as a 
disorder of gut-brain interaction, together with a simple account of the gut-brain axis and how 
this is impacted by diet, stress, cognitive, behavioural, and emotional responses to symptoms, 
and post-infective changes is important. Such an approach may improve patient 
understanding and acceptance of a diagnosis of IBS, and engagement with a shared 
management plan to include an explanation of the mechanisms of action, potential side 
effects, and rationale for the use of drugs or psychological and dietary therapies within the 
context of the gut-brain axis.  
 
Recommendations 
• There is no role for colonoscopy in IBS, other than in those with alarm symptoms or 
signs, or those with symptoms suggestive of IBS with diarrhoea who have atypical 
features and/or relevant risk factors that increase the likelihood of them having 
microscopic colitis (female sex, age ≥50 years, co-existent autoimmune disease, 
nocturnal or severe, watery, diarrhoea, duration of diarrhoea <12 months, weight loss, 
or use of potential precipitating drugs including non-steroidal anti-inflammatory 
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drugs, proton pump inhibitors, etc.) (recommendation: strong, quality of evidence: 
moderate).  
• In those with symptoms suggestive of IBS with diarrhoea, but with atypical features 
such as nocturnal diarrhoea, or a prior cholecystectomy, 23-seleno-25-
homotaurocholic acid scanning or serum 7α-hydroxy-4-cholesten-3-one should be 
considered to exclude bile acid diarrhoea (recommendation: strong, quality of 
evidence: low). 
• In patients with IBS and co-existing symptoms suggestive of a defaecatory disorder or 
faecal incontinence, anorectal physiology tests can be considered, where available, to 
select those who might benefit from biofeedback (recommendation: weak, quality of 
evidence: low).  
• There is no role for testing for exocrine pancreatic insufficiency, or for hydrogen 
breath testing to rule out small intestinal bacterial overgrowth or carbohydrate 
intolerance, in patients with typical IBS symptoms (recommendation: strong, quality 
of evidence: weak). 
• The diagnosis of IBS, its underlying pathophysiology, and the natural history of the 
condition, including common symptom triggers, should be explained to the patient. 
This should introduce the concept of IBS as a disorder of gut-brain interaction, 
together with a simple account of the gut-brain axis and how this is impacted by diet, 
stress, cognitive, behavioural, and emotional responses to symptoms, and post-
infective changes (recommendation: strong, quality of evidence: weak). 
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TREATMENT OF IBS 
General Overview  
The treatment of IBS is generally directed towards the predominant symptom, or 
symptoms, experienced by the patient. All patients should be advised of the potential benefits 
of regular exercise, as there is some evidence from RCTs that this can be beneficial, [150, 
151] particularly for constipation, [150] with beneficial effects still apparent at 5 years in one 
trial. [152] Otherwise, treatment should commence with dietary therapies or first-line drugs, 
according to patient choice, with second-line drugs reserved for those whose symptoms do 
not improve with these measures, due to a combination of the potential side effects, as well as 
the costs, of some of these agents to the health service. Most second-line drugs are only 
available in secondary care. Ideally, the efficacy of selected treatments should be reviewed at 
3 months, and discontinued if no response, with escalation to the next available therapy 
(Figure 2). Currently, psychological therapies are reserved for patients whose symptoms are 
refractory to drugs, although more research is required to explore the efficacy of earlier use, 
and it may be worth mentioning them earlier on so that patients have the option to consider 
them, and so that they are not viewed as a last resort. There should be a realistic discussion 
concerning the limitations of all available treatments for IBS, to manage expectations. It is 
important to stress that cure is unlikely, but substantial improvement in symptoms, social 
functioning, and quality of life is achievable. The final decision regarding treatment choices 
should be made by the patient, with advice and support from the clinician.  
 
Recommendations 
• All patients with IBS should be advised to take regular exercise (recommendation: 
strong, quality of evidence: weak). 
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Methodology for Systematic Reviews of IBS Therapy 
To inform this guideline, we updated a series of systematic reviews and trial-based or 
network meta-analyses conducted by some of the authors. [153-163] The aim was to assess 
the efficacy of dietary modifications and therapies, unlicensed, as well as licensed, 
pharmacological therapies, and psychological therapies in IBS. We considered RCTs 
comparing pharmacological therapies with placebo, psychological therapies with either no 
treatment or standard/usual care, or dietary therapies with standard dietary advice, habitual 
diet, or a sham dietary therapy. Cross-over trials were eligible for inclusion, provided 
extractable data were available at the end of the first treatment period, prior to cross-over. 
Studies recruited adults from primary, secondary, or tertiary care with IBS symptoms 
diagnosed by any criteria (including clinical impression). Trials had to assess the effect of 
treatment in terms of either improvement of IBS symptoms, or improvement of abdominal 
pain, as a dichotomous assessment. It is important to point out that most RCTs of first-line 
treatments, as well as gut-brain neuromodulators and psychological therapies, used less 
rigorous endpoints to judge treatment efficacy, such as improvement in, or satisfactory relief 
of, global symptoms or abdominal pain. Trials of novel second-line drugs, on the other hand, 
tend to use Food and Drug Administration (FDA)-approved endpoints to judge efficacy, 
consisting of a ≥30% improvement in abdominal pain, an increase in the number of complete 
spontaneous bowel movements (CSBMs) per week in IBS-C, or a reduction in the number of 
days with stools of loose consistency in IBS-D, and composites thereof.  
We considered the following treatments: soluble or insoluble fibre, a diet low in 
fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs), a gluten-free diet, 
probiotics, anti-diarrhoeals, antispasmodic drugs (including peppermint oil), laxatives, gut-
brain neuromodulators (tricyclic antidepressants (TCAs) and SSRIs, previously termed 
antidepressant drugs), eluxadoline, 5-HT3 receptor antagonists, antibiotics, secretagogues, 5-
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HT4 receptor agonists, or psychological therapies (including gut-directed hypnotherapy) 
(Supplementary Table 1). As this was an update of prior meta-analyses, [153-163] we 
searched MEDLINE, EMBASE, EMBASE Classic, and the Cochrane central register of 
controlled trials between January 2017 and September 2020. The search strategy is provided 
in the Supplementary Materials. No restrictions were applied regarding language of 
publication. We conducted a recursive search of the bibliography of eligible articles. The lead 
reviewer (ACF) screened titles and trial abstracts that had been identified by the search 
strategy for articles that could possibly be eligible for the review. The lead reviewer (ACF) 
then screened the selected trials to confirm eligibility, using pre-designed eligibility forms. A 
second reviewer (CJB), masked to the initial assessment, also evaluated all identified trials 
for eligibility. We resolved discrepancies by discussion, with a consensus view taken, and 
used the kappa statistic to measure the degree of agreement for judging study eligibility. 
The literature search identified 4111 citations, of which 46 appeared to be relevant, 
and 17 were eligible and were incorporated into this guideline. [164-180] Fourteen of these 
were used to update meta-analyses. [164-177] Agreement between reviewers for study 
eligibility was excellent (kappa statistic = 0.81). Of these 14 studies, two compared 
linaclotide with placebo, [164, 165] and were used to update a previous network meta-
analysis, [155] eight compared various probiotics with placebo, [166-173] and were used to 
update an existing trial-based meta-analysis, [158] and four were RCTs of a low FODMAP 
diet, [174-177] and again were used to update a prior trial-based meta-analysis. [161] The 
remaining three RCTs were an 8-week trial of bimodal release ondansetron in IBS-D, [178] 
and two phase 2 trials of minesapride, [179, 180] a novel 5-HT4 receptor agonist. The results 
of these latter three trials are discussed briefly below. Recommendations for all other 
treatments are, therefore, made based on the results of existing trial-based and network meta-
analyses.  
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All data for newly identified RCTs were extracted independently by two investigators 
(ACF and CJB) on to a Microsoft Excel spreadsheet (XP professional edition; Microsoft 
Corp, Redmond, WA, USA). We resolved disagreements between investigators by discussion. 
We extracted data as intention-to-treat analyses, with all dropouts assumed to be treatment 
failures, wherever trial reporting allowed this. We incorporated data from newly identified 
trials into existing trial-based and network meta-analyses. As we examined binary outcomes, 
(global IBS symptoms or abdominal pain improved or not improved), we expressed the 
impact of each intervention as a relative risk (RR) of global IBS symptoms or abdominal pain 
not improving, together with 95% CIs, where if the RR is less than 1 and the 95% CI does not 
cross 1, there is a significant benefit of the intervention over the control. This approach is the 
most stable, compared with RR of improvement, or using the odds ratio, for some meta-
analyses. [181]  
We used Review Manager version 5.4.1 (RevMan for Windows 2020, the Nordic 
Cochrane Centre, Copenhagen, Denmark) for updates to trial-based meta-analyses. We 
conducted updated network meta-analyses using the frequentist model, with the statistical 
package “netmeta” (version 0.9-0, https://cran.r-
project.org/web/packages/netmeta/index.html) in R (version 4.0.2). Network meta-analysis 
usually gives a more precise estimate, compared with results from standard, trial-based meta-
analysis. [182, 183] It can also rank treatments to inform clinical decisions, [184] according 
to their P-score, which is a value between 0 and 1, with higher scores indicating a greater 
probability of a treatment being ranked as best. [185] For both trial-based and network meta-
analyses, we pooled data using a random effects model, to give a more conservative estimate 
of the efficacy of individual therapies, [186] and assessed heterogeneity using the I2 statistic, 
which ranges from 0% to 100%, with 0% representing no observed heterogeneity, and larger 
values indicating increasing heterogeneity. A value ≤50% was chosen to represent low levels 
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of heterogeneity. [187]  
 
Fibre and Dietary Therapies 
Over 80% of individuals with IBS report food-related symptoms, especially to 
fermentable carbohydrates and fats. [188, 189] Patients reporting adverse food reactions 
experience more severe gastrointestinal symptoms, associated subjective health complaints of 
musculoskeletal pains and chronic fatigue, and reduced quality of life, compared with those 
without food sensitivities. [189-191] Hence, most patients with IBS are keen to explore 
dietary options, with over 60% wanting to know what food(s) they should avoid, and up to 
70% having modified their diet. [192] There are multiple mechanisms by which food may 
trigger symptoms in IBS, including primary effects (e.g., osmotic, chemical, immunological, 
mechanical, or neuroendocrine) and secondary effects (e.g., fermentation by-products, 
alterations in intraluminal pH, or effects on the gut microbiome). [193, 194] 
Patients may seek to undertake dietary manipulations based on tests that suggest 
potential food intolerances. A prior RCT, comprising 150 patients with IBS and positive IgG 
antibodies to food, found a significant improvement in symptoms in those allocated to a true-
exclusion diet, compared with a sham-exclusion diet. [195] However, the effect was modest 
and there are concerns regarding the poor specificity and applicability of IgG antibody 
testing. [196] For example, IgG antibodies to yeast were reported in 87% of patients yet are 
rarely responsible for symptoms following dietary re-challenges. [195, 196] Hence, food 
elimination diets based on IgG antibodies are not recommended. Although some studies have 
identified potential food intolerances via leukocyte antigen testing of peripheral blood 
samples or real-time confocal laser endomicroscopy, this requires further corroboration. [68, 
197] 
In clinical practice, the last decade has seen a growing interest in the use of three diets 
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for IBS, which are traditional dietary advice, a low FODMAP diet, or a gluten-free diet. Of 
these, traditional dietary advice is considered as first-line, and is based upon guidance 
produced by NICE and the British Dietetic Association (BDA). [198, 199] Its principles, 
which do not require formal dietetic input, include adopting healthy eating patterns, such as 
regular meals, maintaining adequate nutrition, limiting alcohol and caffeine intake, adjusting 
fibre intake, and reducing consumption of fatty and spicy foods. However, the evidence for 
this is based on a combination of clinical experience and the potential mechanisms by which 
these foods may induce gastrointestinal symptoms in IBS, rather than evidence from RCTs of 
this approach versus a control treatment. With regards to fibre, a systematic review and meta-
analysis of 15 RCTs, comprising 946 patients, demonstrated its benefit in IBS (RR of 
symptoms persisting = 0.87; 95% CI 0.80 to 0.94) (Supplementary Figure 1). [158] However, 
this effect was limited to soluble fibre, such as ispaghula (RR = 0.83; 95% CI 0.73 to 0.94), 
but not insoluble fibre, like wheat bran, which may exacerbate abdominal pain and bloating. 
It is generally advised to start with low doses of soluble fibre (3-4g daily) and build up 
gradually, as tolerated, to a total dosage of 20-30g/day, as it increases colonic water content 
and volume, [200] which may aggravate abdominal pain and bloating. 
A low FODMAP diet is recommended as a second-line diet for IBS. [10, 198] 
FODMAPS are short-chain fermentable carbohydrates that are found in a variety of fruits, 
vegetables, dairy products, artificial sweeteners, and wheat. They increase small intestinal 
water volume and colonic gas production and, in those with visceral hypersensitivity, induce 
gastrointestinal symptoms. [201] They may also trigger bowel symptoms as they produce 
short chain fatty acids, which lower colonic pH. [202] Hence, the benefits of adopting a low 
FODMAP diet in IBS seem physiologically plausible and several RCTs have evaluated its 
efficacy in IBS. The update to the prior systematic review and meta-analysis, [161] used to 
inform this guideline, identified 11 trials comparing a low FODMAP diet with various dietary 
Vasant, Paine et al.         Page 49 of 133 
 
control interventions, including habitual diet, a high FODMAP diet, traditional dietary advice 
as recommended by NICE and the BDA, or a sham diet, in 658 participants. A low FODMAP 
diet was associated with a reduction in the risk of remaining symptomatic, compared with all 
control interventions (RR = 0.71; 95% CI 0.61 to 0.83) (Supplementary Figure 2). However, 
as reported in the prior meta-analysis, [161] the quality of evidence from these trials was very 
low, due to small sample sizes, difficulties in blinding, and heterogeneity between studies. 
The latter has mainly been attributed to the various control interventions used. Interestingly, 
those studies that compared the low FODMAP with traditional dietary advice from NICE and 
the BDA had the least heterogeneity, but also the least magnitude of effect (RR = 0.82; 95% 
CI 0.67 to 1.01), suggesting that the 50% to 70% symptomatic benefit reported for a low 
FODMAP diet in some studies may have been over-estimated. Moreover, RCTs have focused 
solely on the initial “elimination” phase of the low FODMAP diet, which lasts between 4 and 
6 weeks, not the subsequent reintroduction and long-term “personalisation” phase. The effect 
of FODMAP reintroduction to tolerance on IBS symptoms is therefore unclear, although 
there have been open-label studies reporting the long-term efficacy of an adapted low 
FODMAP diet ranges somewhere between 50% and 60%. [177, 203] 
Finally, some patients with IBS report symptomatic benefit from a gluten-free diet 
despite no objective evidence of coeliac disease. [204] The prior systematic review and meta-
analysis identified only two RCTs, [161] comprising 111 participants and noted that although 
a gluten-free diet was associated with a reduction in global symptoms compared with a 
control diet, this was not statistically significant (RR = 0.42; 95% CI 0.11 to 1.55). There is, 
therefore, insufficient evidence to recommend a gluten-free diet routinely in IBS, although 
given its widespread popularity further RCTs are needed. It has also been suggested that the 
clinical benefit reported with a gluten-free diet is, in the main, not due to the removal of 
gluten per se, but rather a reduction in dietary fructan content, which is a FODMAP, resulting 
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from wheat exclusion. [205, 206] Future trials comparing a gluten-free diet head-to-head with 
a low FODMAP diet with regards to efficacy, convenience, cost, and acceptability, may better 
inform patient choice.  
Issues with following a low FODMAP diet, as opposed to traditional dietary advice, 
include the need for a specialist dietitian to implement it, followed by close monitoring to 
avoid nutritional deficiencies or the development of overly restrictive eating habits. [207-209] 
The latter emphasises the importance of screening out patients at high risk for such behaviour 
prior to recommending such diets. [207-209] This can be achieved using simple eating 
disorder questionnaires (e.g., SCOFF), applying these carefully and with empathy, to identify 
those with high levels of psychological distress. [210, 211] Moreover, a low FODMAP diet 
may induce detrimental changes to the gut microbiota, with reductions in Bifidobacteria and 
total bacterial count, [212] although the long-term consequences of this are unknown. Future 
studies should aim to identify actionable biomarkers that might predict response to a given 
dietary intervention. Preliminary data suggests that response to a low FODMAP may be 
predicted from baseline faecal bacterial profile and metabolomic activity, whilst a gluten-free 
diet may benefit those with serum anti-gliadin antibodies. [213-215] 
 
Recommendations 
• First-line dietary advice should be offered to all patients with IBS (recommendation: 
strong, quality of evidence: weak). 
• Food elimination diets based on IgG antibodies are not recommended in patients with 
IBS (recommendation: strong, quality of evidence: moderate).  
• Soluble fibre, such as ispaghula, is an effective treatment for global symptoms and 
abdominal pain in IBS, but insoluble fibre (e.g., wheat bran) should be avoided as it 
may exacerbate symptoms. Soluble fibre should be commenced at a low dose (3-
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4g/day) and built up gradually to avoid bloating (recommendation: strong; quality of 
evidence: moderate). 
• A diet low in fermentable oligo-, di-, and monosaccharides and polyols, as a second-
line dietary therapy, is an effective treatment for global symptoms and abdominal pain 
in IBS, but its implementation should be supervised by a trained dietitian and 
fermentable oligo-, di-, and monosaccharides and polyols should be reintroduced 
according to tolerance (recommendation: weak, quality of evidence very low).  
• A gluten-free diet is not recommended in IBS (recommendation: weak, quality of 
evidence very low) 
 
Probiotics 
The faecal microbiome of patients with IBS may differ significantly from that of 
healthy individuals. [216] The theory that this might, in part, be involved in pathophysiology 
has led to interest in whether probiotics, which are live or attenuated microorganisms that 
may have beneficial effects in humans, can be used to alter the microbiome, improving 
symptoms. We updated a prior meta-analysis of 37 RCTs, [158] incorporating data from eight 
new trials, [166-173] and randomising 6352 patients. Sub-group analyses according to type of 
probiotic used (where more than one trial of a particular group of probiotics was conducted) 
demonstrated significant effects on global symptoms or abdominal pain for combinations of 
probiotics (RR = 0.79; 95% CI 0.70 to 0.89), Lactobacillus (RR = 0.75; 95% CI 0.60 to 0.94), 
Bifidobacterium (RR = 0.80; 95% CI 0.70 to 0.91), and Escherichia (RR = 0.86; 95% CI 0.79 
to 0.93) (Supplementary Figure 3). Adverse event rates were similar in the probiotic and 
placebo arms. Variations in study design, strain and species of probiotic used, and 
heterogeneity between studies make it difficult to give specific recommendations. However, 
it is reasonable to advise patients wishing to try probiotics to take them for up to 12 weeks, 
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and to discontinue treatment if there is no improvement in symptoms. 
 
Recommendations 
• Probiotics, as a group, may be an effective treatment for global symptoms and 
abdominal pain in IBS, but it is not possible to recommend a specific species or strain. 
It is reasonable to advise patients wishing to try probiotics to take them for up to 12 
weeks, and to discontinue them if there is no improvement in symptoms 
(recommendation: weak, quality of evidence: very low). 
 
Drugs Used First Line for IBS 
Loperamide is a synthetic μ-opioid agonist that reduces myenteric plexus activity, 
thereby increasing intestinal transit time, and enhancing water reabsorption. A prior 
systematic review identified only two RCTs of loperamide in IBS-D and IBS-M containing 
42 patients. [160] Although the drug improved stool frequency and consistency, it had no 
effect on global symptoms (RR = 0.44; 95% CI 0.14 to 1.42). The incidence of adverse 
events with loperamide was similar to placebo in these trials. However, in clinical practice, 
abdominal pain, bloating, nausea, and constipation are common side effects, and may limit 
tolerability. Titrating the dose carefully may improve tolerability. 
Antispasmodics are amongst the most frequently used over-the-counter treatments for 
IBS, and can be divided, broadly, into antimuscarinics and smooth muscle relaxants. 
Antimuscarinics, including dicycloverine, propantheline, otilonium bromide, and hyoscine 
butylbromide reduce intestinal motility, whereas alverine and mebeverine are direct-acting 
intestinal smooth muscle relaxants. The proposed mechanism of action of these agents is 
based on the assumption that some IBS symptoms are a result of gastrointestinal spasm and 
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dysmotility, which antispasmodics ameliorate. [217] A prior meta-analysis identified 26 
RCTs, containing 2811 patients, which compared 13 different antispasmodics with placebo. 
[160] Despite significant heterogeneity between trials, presumably driven by differences in 
antispasmodics studied, patient selection, and study design, fewer patients treated with 
antispasmodics had persistent global symptoms or abdominal pain (RR = 0.65; 95% CI 0.56 
to 0.76) (Supplementary Figure 4). However, these findings should be interpreted with 
caution, given heterogeneity between trial results and the varying endpoints studied. In 
addition, most trials recruited unselected patients with IBS, so whether the proposed 
reduction in gastrointestinal motility with antispasmodics improves diarrhoea is unclear. 
Access to some of these drugs is limited, although hyoscine butylbromide is available widely; 
pooled results from three RCTs, containing 426 patients, demonstrated efficacy (RR = 0.63; 
95% CI 0.51 to 0.78) (Supplementary Figure 4). [160] In contrast, in this meta-analysis, 
neither alverine nor mebeverine demonstrated benefit over placebo. The overall rates of 
adverse events were significantly higher with antispasmodics compared with placebo; most 
notably dry mouth, visual disturbance, and dizziness. [160] 
Peppermint oil is another popular over-the-counter remedy for IBS. Although not 
completely understood, its putative antispasmodic action is via L-menthol’s blockade of 
calcium channels. [218] A meta-analysis of eight RCTs, which included 823 patients, has 
evaluated its efficacy. [162] For global symptoms or abdominal pain, peppermint oil was 
more efficacious than placebo (RR = 0.58; 0.34 to 0.98) (Supplementary Figure 5). It should 
be stressed that these trials involved specific formulations of peppermint oil. Their results, 
therefore, cannot be extrapolated to other formulations and, in the largest trial to date 
included in this meta-analysis, which used two formulations of variable release peppermint 
oil (small bowel vs. ileocolonic) there was no benefit over placebo for the primary endpoint. 
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[219] In addition, low study quality, the lack of consistent use of the Rome criteria to define 
IBS, and heterogeneity between RCTs limit confidence in the data. There is also a lack of 
information as to which IBS subtype would benefit most. Overall adverse events with 
peppermint oil were no more common than placebo, [160] although patients can report 
gastro-oesophageal reflux symptoms due to its effects on the lower oesophageal sphincter. 
Comparison of peppermint oil and antispasmodics with other unlicensed or “traditional” 
treatments for IBS, including ispaghula and gut-brain neuromodulators, in a network meta-
analysis suggested that, for global symptoms, peppermint oil was ranked first and 
antispasmodics third, with both superior to placebo (Supplementary Figure 6). [157] In terms 
of effect on abdominal pain, antispasmodics ranked second, with peppermint oil third 
(Supplementary Figure 7). Again, both were significantly more efficacious than placebo. 
Current NICE guidance for the management of IBS suggests that patients with IBS-C 
can be treated with laxatives, advising dose titration according to symptoms. [10] Although 
both stimulant and osmotic laxatives are efficacious in the treatment of chronic idiopathic 
constipation, [220] only the latter have been evaluated in two RCTs of polyethylene glycol, 
recruiting 181 patients with IBS-C. [221, 222] In one trial, there was no significant effect on 
either abdominal pain or number of bowel movements, [221] and in the second the number of 
bowel movements increased significantly, but with no improvement in abdominal pain. [222] 
Polyethylene glycol was generally well-tolerated with abdominal pain the most frequent 
adverse event. The longer-term efficacy of osmotic laxatives in IBS-C is unknown, as both 
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Recommendations 
• Loperamide may be an effective treatment for diarrhoea in IBS. However, abdominal 
pain, bloating, nausea, and constipation are common, and may limit tolerability. 
Titrating the dose carefully may avoid this (recommendation: strong; quality of 
evidence: very low). 
• Certain antispasmodics may be an effective treatment for global symptoms and 
abdominal pain in IBS. Dry mouth, visual disturbance, and dizziness are common side 
effects (recommendation: weak, quality of evidence: very low). 
• Peppermint oil may be an effective treatment for global symptoms and abdominal 
pain in IBS. Gastro-oesophageal reflux is a common side effect (recommendation: 
weak, quality of evidence: very low). 
• Polyethylene glycol may be an effective treatment for constipation in IBS. Abdominal 
pain is a common side effect (recommendation: weak; quality of evidence: very low). 
 
Gut-brain Neuromodulators 
Dysfunction within the bidirectional gut-brain axis is considered to play an important 
role in the genesis and maintenance of symptoms in IBS. Although IBS is often considered a 
functional gastrointestinal disorder these conditions have, therefore, been re-termed as 
disorders of gut-brain interaction. [32] Patients with IBS often have co-morbid anxiety and 
depression, [119] and these are also risk factors for the subsequent development of IBS in 
healthy people. [31] This, together with their peripheral effects on gastrointestinal function, 
[223] is part of the rationale for the use of gut-brain neuromodulators, such as TCAs and 
SSRIs. In a meta-analysis of 12 RCTs of TCAs, recruiting 787 patients, these drugs were 
superior to placebo for global symptoms or abdominal pain (RR = 0.65; 95% CI 0.55 to 0.77) 
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(Supplementary Figure 8), and for abdominal pain alone (RR = 0.59; 95% CI 0.42 to 0.83) 
(Supplementary Figure 9). [159] SSRIs were also more efficacious for global symptoms or 
abdominal pain (RR = 0.68; 95% CI 0.51 to 0.91) (Supplementary Figure 8), but not 
abdominal pain alone (Supplementary Figure 9), and there was significant heterogeneity 
amongst the seven trials, which contained only 356 patients. [159] Adverse event rates were 
significantly higher among patients treated with TCAs or SSRIs, with drowsiness and dry 
mouth the most common. [159] The effect of these drugs on stool pattern is less clear, as very 
few trials restricted their recruitment to a particular sub-group of patients.  
Other gut-brain neuromodulators include serotonin norepinephrine reuptake inhibitors 
(SNRIs), such as duloxetine, or agents acting on the calcium channel α2δ ligand, including 
pregabalin. There have been no RCTs of SNRIs in IBS, although there is evidence from case 
series that duloxetine may improve symptoms and quality of life, [224, 225] and there is good 
evidence for use of SNRIs in other chronic painful disorders, such as fibromyalgia and low 
back pain. [226] Pregabalin improved visceral hypersensitivity in one small trial, [227] and in 
a recent RCT recruiting 85 patients with IBS, 12 weeks of pregabalin 225mg twice daily led 
to significant improvements in global symptoms, abdominal pain, diarrhoea, and bloating 
versus placebo. [228] Blurred vision, dizziness, and altered sensation were more common 
with pregabalin. However, more RCTs are needed, and pregabalin is classed as a controlled 
drug in some countries. In a network meta-analysis evaluating relative efficacy of gut-brain 
modulators with other unlicensed or “traditional” treatments, [157] TCAs were ranked second 
and first for their effect on global symptoms and abdominal pain respectively, and were more 
efficacious than placebo (Supplementary Figures 6 and 7). In contrast, SSRIs were ranked 
fifth and fourth for global symptoms and abdominal pain respectively, and pregabalin was 
ranked sixth for global symptoms, with no benefit of either over placebo in these trials. 
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It is reasonable to consider using TCAs second line to treat global symptoms or 
abdominal pain or SSRIs second line to treat global symptoms, or if there is co-existent 
anxiety. [226] They can be offered by primary care physicians, depending on familiarity of 
use and expertise. The rationale for the use of gut-brain neuromodulators, as well as their side 
effect profile, needs to be explained carefully to the patient, within the context of IBS as a 
disorder of gut-brain interaction. [226] It should be reinforced that these drugs are being used 
at low doses for their pain modulatory properties and peripheral effects on gastrointestinal 
function, rather than at a dose that is used to treat common mental disorders. TCAs should be 
taken in the evening, before bedtime, due to their sedating effects, and may also improve 
sleep patterns. The patient should be counselled that these drugs take some time to have any 
benefit and that side effects, such as drowsiness, tend to ameliorate after the first 1 or 2 weeks 
of treatment. They should be commenced at a low dose (e.g., 10mg of amitriptyline o.d.) and 
titrated relatively slowly in 10mg increments, to a maximum of 30mg to 50mg o.d., with 
follow-up to assess efficacy and tolerability. If beneficial, the drugs are likely to be continued 
for a minimum of 6 to 12 months and, in some cases, this may be even longer-term. 
 
Recommendations 
• Tricyclic antidepressants used as gut-brain neuromodulators are an effective second-
line drug for global symptoms and abdominal pain in IBS. They can be initiated in 
primary or secondary care, but careful explanation as to the rationale for their use is 
required, and patients should be counselled about their side effect profile. They should 
be commenced at a low dose (e.g., 10mg amitriptyline o.d.) and titrated slowly to a 
maximum of 30mg to 50mg o.d. (recommendation: strong, quality of evidence: 
moderate).  
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• Selective serotonin reuptake inhibitors used as gut-brain neuromodulators may be an 
effective second-line drug for global symptoms in IBS. As with tricyclic 
antidepressant, they can be initiated in primary or secondary care, but careful 
explanation as to the rationale for their use is required, and patients should be 
counselled about their side effect profile. (recommendation: weak, quality of 
evidence: low).  
 
Drugs Used Second Line for the Treatment of IBS-D 
 For patients with IBS-D who do not experience symptom improvement with anti-
diarrhoeals, several licensed therapies are available in secondary care. Eluxadoline is a μ-
opioid and κ-opioid receptor agonist and δ-opioid receptor antagonist licensed for IBS-D. The 
drug slows intestinal transit and reduces visceral hypersensitivity. [229] Data from a meta-
analysis (four RCTs containing 3122 patients) demonstrated that both 75mg b.i.d. and 100mg 
b.i.d. were superior to placebo using the FDA-approved composite endpoint for IBS-D, 
consisting of improvement in abdominal pain and stool consistency (RR = 0.89; 95% CI 0.84 
to 0.94, and RR = 0.87; 95% CI 0.83 to 0.91, respectively) (Supplementary Figure 10), global 
symptoms, and stool consistency (Supplementary Figures 11 and 12). [153] Eluxadoline 
100mg b.i.d. was also superior to placebo for abdominal pain (Supplementary Figure 13). 
Adverse events included constipation, nausea, and headache, and adverse events leading to 
drop out were significantly higher with active drug than placebo. Serious adverse events, 
including pancreatitis and sphincter of Oddi spasm, have been reported, occurring in 0.5% of 
patients in these trials. [230] The drug is contraindicated in patients with prior sphincter of 
Oddi problems or cholecystectomy, alcohol dependence, pancreatitis, or severe liver 
impairment. Although licensed for IBS-D, the drug is unavailable in many countries. 
Drugs acting as antagonists at the 5-HT3 receptor are also licensed for IBS-D. These 
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include alosetron and ramosetron, which slow gastrointestinal transit, reduce visceral 
hypersensitivity, and alter rectal compliance. [231-233] In a previous meta-analysis, [153] 
both alosetron 1mg b.i.d. and ramosetron 2.5mcg or 5mcg o.d. were superior to placebo 
across various endpoints, including the FDA composite endpoint for IBS-D (three RCTs of 
alosetron 1mg b.i.d., 787 patients, RR = 0.69; 95% CI 0.60 to 0.80, and one RCT of 
ramosetron 2.5mcg o.d., 348 patients, RR = 0.78; 95% CI 0.67 to 0.91) (Supplementary 
Figure 10). Both drugs were also more efficacious than placebo for global symptoms, 
abdominal pain, and stool consistency (Supplementary Figures 11 to 13). Adverse events 
included constipation, nausea, and headache; patients assigned to both drugs were more likely 
to report adverse events than with placebo. Alosetron was withdrawn from the market in 2001 
due to reports of ischaemic colitis. [234] However, it was reintroduced in the USA via a risk 
evaluation and mitigation strategy, at a lower dose of 0.5mg b.i.d., for women with severe 
IBS-D. Rates of ischaemic colitis observed since reintroduction are similar to the background 
rate in female patients with IBS. [235] Ramosetron is only available in Asia. [153] There 
have been no reports of ischaemic colitis associated with the drug. Due to the limited 
availability of both alosetron and ramosetron, RCTs of ondansetron, a widely available 5-HT3 
receptor antagonist with a robust safety profile, have been conducted. A small crossover trial 
of ondansetron titrated from 4mg o.d. to a maximum of 8mg t.i.d. demonstrated significantly 
higher rates of improvement in urgency, bloating, and stool consistency, but not abdominal 
pain. [236] A subsequent RCT of 12mg o.d. of bimodal release ondansetron also 
demonstrated superiority over placebo for improvement in stool consistency, but not 
abdominal pain. [178] Constipation is the most common side effect. Results from a parallel-
group RCT are awaited. [237] 
 The efficacy of rifaximin, a non-absorbable antibiotic, has also been tested in IBS-D, 
on the basis that disturbances in the gastrointestinal microbiota may, in part, be responsible 
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for symptoms. In a meta-analysis of two RCTs, [153] which recruited 1260 patients, 
rifaximin 550mg t.i.d. for 14 days was more efficacious than placebo for the FDA composite 
endpoint for IBS-D (RR = 0.92; 95% CI 0.86 to 0.98) (Supplementary Figure 10) and for 
stool consistency alone (Supplementary Figure 12), but not for global symptoms or 
abdominal pain (Supplementary Figures 11 and 13). Headache was the most common adverse 
event, but side effects were no more common with rifaximin than with placebo. Due to the 
modest efficacy, and concerns over the potential for adverse events (including C. difficile 
infection and bacterial resistance) with repeated courses of rifaximin, FDA approval was not 
forthcoming. A subsequent “re-treatment” trial was therefore conducted. In this RCT patients 
received open-label rifaximin and were then randomised to two repeat 14-day courses of 
rifaximin or placebo if they experienced symptom relapse. Significantly more patients 
experienced an improvement in global symptoms with rifaximin after each treatment course, 
and there were no safety concerns. [238] The drug is now licensed for IBS-D in the USA but 
is not available for this indication in many countries.  
 A network meta-analysis comparing the relative efficacy of all these licensed 
therapies for IBS-D, across various endpoints, [153] demonstrated that alosetron 1mg b.i.d. 
ranked first for the FDA composite endpoint for IBS-D and global symptoms (Supplementary 
Figures 10 and 11), with ramosetron 2.5mcg o.d. second. For the FDA composite endpoint, 
alosetron was superior to all treatments, except ramosetron 2.5mcg o.d. For, abdominal pain, 
ramosetron 2.5mcg o.d. and ramosetron 5mcg o.d. were ranked first and second respectively 
(Supplementary Figure 13). Finally, for stool consistency alosetron 1mg b.i.d. ranked first, 
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Recommendations 
• Eluxadoline, a mixed opioid receptor drug, is an efficacious second-line drug for IBS 
with diarrhoea in secondary care. It is contraindicated in patients with prior sphincter 
of Oddi problems or cholecystectomy, alcohol dependence, pancreatitis, or severe 
liver impairment, and lack of availability may limit its use (recommendation: weak, 
quality of evidence: moderate).  
• 5-HT3 receptor antagonists are efficacious second-line drugs for IBS with diarrhoea in 
secondary care. Alosetron and ramosetron are unavailable in many countries; 
ondansetron titrated from a dose of 4mg o.d. to a maximum of 8mg t.i.d. is a 
reasonable alternative. Constipation is the most common side effect. This drug class is 
likely the most efficacious for IBS with diarrhoea (recommendation: weak, quality of 
evidence: moderate to high).  
• The non-absorbable antibiotic rifaximin is an efficacious second-line drug for IBS 
with diarrhoea in secondary care, although its effect on abdominal pain is limited. The 
drug is licensed for IBS with diarrhoea in the USA but is not available for this 
indication in many countries (recommendation: weak, quality of evidence: moderate).  
 
Drugs Used Second Line for the Treatment of IBS-C 
In patients with IBS-C who do not experience symptom improvement with laxatives, 
escalation to second-line drugs should be considered in secondary care. These fall into two 
main classes, secretagogues and 5-HT4 agonists. Secretagogues, including linaclotide, 
lubiprostone, plecanatide, and tenapanor activate ion channels on the intraluminal surface of 
enterocytes, resulting in an efflux of ions and water into the intestinal lumen, softening stools 
and accelerating transit. [239, 240] Linaclotide is a peptide that acts as a guanylate cyclase-C 
agonist. Lubiprostone is a prostaglandin E1 derivative, which activate chloride type-2 
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channels. Plecanatide is another guanylate cyclase-C agonist that binds in a pH-dependent 
manner, in contrast to linaclotide, such that the majority of its activity is confined to the 
proximal small bowel. [241] Tenapanor is a small molecule inhibitor of the gastrointestinal 
sodium-hydrogen exchanger-3. 5-HT4 agonists, such as tegaserod, have prokinetic effects and 
also accelerate transit. [242] Abdominal bloating is a particularly troublesome symptom in 
patients with IBS-C, [46] and the effects of all these drugs on this symptom, other than 
plecanatide, has been assessed in some RCTs. 
In an update of a previous meta-analysis, [155] a dose of 290mcg o.d. linaclotide was 
superior to placebo in five RCTs, containing 3193 patients, for the FDA composite endpoint 
for IBS-C, consisting of improvement in abdominal pain and an increase of ≥1 CSBMs per 
week from baseline (RR = 0.82; 95% CI 0.78 to 0.87) (Supplementary Figure 14), abdominal 
pain alone (Supplementary Figure 15), and an increase of ≥1 CSBMs per week from baseline 
(Supplementary Figure 16). The drug was also superior to placebo in terms of an 
improvement in abdominal bloating in four trials containing 3061 patients (Supplementary 
Figure 17). Adverse events were significantly more common with linaclotide 290mcg o.d., 
with diarrhoea being the most common. Lubiprostone 8mcg b.i.d. was superior to placebo for 
both the FDA composite endpoint for IBS-C (RR = 0.87; 95% CI 0.78 to 0.96) 
(Supplementary Figure 14) and abdominal pain alone (Supplementary Figure 15) in this 
meta-analysis, using a post hoc analysis of data from two phase III RCTs, containing 452 
patients. [155] The drug was superior to placebo for abdominal bloating in these two RCTs 
(Supplementary Figure 17). Adverse events were no more common with lubiprostone, except 
for nausea. In the same meta-analysis, [155] both plecanatide 3mcg o.d. and 6mcg o.d. were 
superior to placebo for the FDA composite endpoint (RR = 0.88; 95% CI 0.82 to 0.94 for 
3mcg o.d. in three RCTs, recruiting 1632 patients, and RR = 0.87; 95% CI 0.81 to 0.93 for 
6mcg o.d. in two RCTs, containing 1461 patients) (Supplementary Figure 14) and abdominal 
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pain alone (Supplementary Figure 15), but not for an increase of ≥1 CSBMs per week from 
baseline (Supplementary Figure 16). Adverse events were significantly more frequent with 
plecanatide 3mcg o.d., compared with placebo, and diarrhoea was significantly more likely 
with both doses. Finally, three RCTs of tenapanor 50mg b.i.d., recruiting 1428 patients, were 
included in this meta-analysis. [155] The RR for the FDA composite endpoint, compared 
with placebo, was 0.85 (95% CI 0.79 to 0.92) (Supplementary Figure 14). The drug was also 
more efficacious than placebo for abdominal pain (Supplementary Figure 15) and an increase 
of ≥1 CSBMs per week from baseline (Supplementary Figure 16). Again, the drug was more 
likely to improve abdominal bloating than placebo in three trials containing 1428 patients 
(Supplementary Figure 17). Except for diarrhoea, adverse events were no more likely with 
the drug than with placebo.  
A previous meta-analysis of 11 RCTs demonstrated that tegaserod was superior to 
placebo for the treatment of IBS-C in 9242 patients (RR = 0.85; 95% CI 0.80 to 0.90) 
(Supplementary Figure 18). [163] Diarrhoea was the most common adverse event and was 
significantly more likely than with placebo. Due to a small excess number of cerebrovascular 
and cardiovascular ischaemic events in patients taking the drug, it was withdrawn in 2007. 
Tegaserod was reintroduced in the USA in 2018 for female patients <65 years of age with 
IBS-C without pre-existing cardiovascular disease, based on a post hoc analysis of three large 
trials reporting efficacy according to the FDA composite endpoint for IBS-C. In a meta-
analysis using data from these three trials, containing 2472 patients, the drug was superior to 
placebo (RR = 0.85; 95% CI 0.80 to 0.91) (Supplementary Figure 14). [154] Finally, 
tegaserod was superior to placebo for abdominal bloating in four RCTs, containing 5132 
patients (Supplementary Figure 17). Although prucalopride, which is a highly selective 5-HT4 
agonist with no known cardiovascular or cerebrovascular safety concerns, is efficacious in the 
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treatment of chronic idiopathic constipation, [220] to date there have been no RCTs in IBS-C.  
A network meta-analysis examining the relative efficacy of secretagogues and 
tegaserod across 18 RCTs, in 10,638 patients, demonstrated that all drugs were superior to 
placebo. [154, 155] Linaclotide 290mcg o.d. ranked first across all endpoints, including 
abdominal bloating (Supplementary Figures 14 to 16 and Supplementary Figure 19), but on 
indirect comparison of active treatments there were no significant differences between 
individual drugs and dosages.  
 
Recommendations 
• Linaclotide, a guanylate cyclase-C agonist, is an efficacious second-line drug for IBS 
with constipation in secondary care. It is likely to be the most efficacious 
secretagogue available for IBS with constipation, although diarrhoea is a common 
side effect (recommendation: strong, quality of evidence: high).  
• Lubiprostone, a chloride channel activator, is an efficacious second-line drug for IBS 
with constipation in secondary care. This secretagogue is less likely to cause 
diarrhoea than others. However, patients should be warned that nausea is a frequent 
side effect (recommendation: strong, quality of evidence: moderate).  
• Plecanatide, another guanylate cyclase-C agonist, is an efficacious second-line drug 
for IBS with constipation in secondary care. Diarrhoea is a common side effect and is 
no less likely than with linaclotide or tenapanor. Although the drug is licensed for IBS 
with constipation in the USA, it is not yet available for this indication in many 
countries (recommendation: strong, quality of evidence: high).  
• Tenapanor, a sodium-hydrogen exchange inhibitor, is an efficacious second-line drug 
for IBS with constipation in secondary care. Again, diarrhoea is a frequent side effect. 
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Although the drug is licensed for IBS with constipation in the USA, it is not yet 
available for this indication in many countries (recommendation: strong, quality of 
evidence: high).  
• Tegaserod, a 5-HT4 receptor agonist, is an efficacious second-line drug for IBS with 
constipation in secondary care but is unavailable outside the USA. Diarrhoea is a 
common side effect (recommendation: strong, quality of evidence: moderate).  
 
Psychological Therapies 
A recent network meta-analysis of RCTs of psychological therapies for IBS 
demonstrated that several psychological therapies were more efficacious than control 
interventions. [156] However, the most compelling evidence, based on the number of trials 
and longer-term outcomes was for cognitive behavioural therapy (CBT) and gut-directed 
hypnotherapy, [156] both of which are recommended by the NICE guideline when symptoms 
have not improved after 12 months of drug treatment. [10] 
The principles of CBT are based upon the five systems model, which suggests that 
cognitions (thoughts), behaviours (actions), emotions, and physiology all interact within the 
context of the broader environment or social system. By altering any of these systems, others 
can potentially be modified (e.g., changing one’s thoughts can alter one’s emotions, as well as 
one’s physiological responses). Although there is a core set of defined therapeutic techniques 
employed in all variants of CBT, the underlying formulations of the therapy differ, depending 
on the primary outcome. For instance, if reducing depression is the primary outcome the 
therapy focuses on increasing pleasurable activities and challenging alternative negative 
thoughts about the self. If anxiety is the outcome, the therapy focuses on reducing avoidance 
of threatening situations and threat-related thought patterns. 
The network meta-analysis of psychological interventions for IBS, which included 15 
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trials of CBT in 1844 patients, concluded that CBT delivered in several formats was more 
effective than a control, including education and support, treatment as usual, and a waiting 
list control (Supplementary Figure 20). [156] Face-face CBT (10 RCTs, 930 patients, RR = 
0.62; 95% CI 0.48 to 0.80), self-administered or minimal contact CBT (four trials, 434 
patients, RR = 0.61; 95% CI 0.45 to 0.83), therapist-delivered CBT over the telephone (one 
RCT, 373 patients, RR = 0.50; 95% CI 0.29 to 0.84) and group CBT (two trials, 50 patients, 
RR = 0.41; 95% CI 0.19 to 0.91) were all superior to a waiting list control. [156] There was 
substantial heterogeneity in some of the estimates, which may, in part, be explained by 
differences in trial design, sample size, and whether patients with refractory IBS were 
included. Analysis of trials that only included patients with refractory symptoms reduced the 
heterogeneity, and still demonstrated efficacy for CBT in some formats (Supplementary 
Figure 21).  
Other sources of heterogeneity may include hours of therapy time. For example, 
within the face-to-face CBT groups therapist time ranged from 5 to 12 hours. Of the two 
web-based interventions, one had eight online interactive sessions with 2.5 hours of telephone 
therapist support, and the other five online sessions with e-mail support. There were also 
differences in the skill level of therapists across trials. Most were experienced CBT therapists, 
but some trials used doctoral level students, and one RCT trained nurses to deliver CBT. The 
CBT protocols themselves varied. Some made IBS-specific modifications to existing mental 
health protocols, and others were based on stress management related to IBS.  
The two most recent, and largest, RCTs used CBT developed specifically for IBS. [86, 
243] In both, this included education concerning the role of stress in IBS, stress management 
techniques, cognitive techniques to identify and challenge both unhelpful thoughts associated 
with IBS and core beliefs around perfectionism, and relapse prevention. The ACTIB trial also 
included a description of the pathophysiology of key symptoms, and how CBT may work 
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through the gut-brain axis. [86] Other sections focused on altering IBS-specific safety and 
avoidance behaviours (e.g., not going out until bowels are empty, or a toilet location is 
known) and managing negative emotions. The IBSOS trial included problem-solving training 
focused on coping with IBS stressors. [243] 
The rationale for IBS-specific CBT is further supported by a review of the 
psychological mechanisms of CBT for IBS. [30] Key mechanisms related to reduction in IBS 
symptom severity appear to be changes in IBS-specific cognitions and gastrointestinal-
specific anxiety, rather than changes in general anxiety. With respect to this issue, it is worth 
noting that in the largest trial of CBT for IBS conducted to date at least 50% of patients met 
cut-offs for probable common mental disorders at baseline, and both therapist-delivered CBT 
over the telephone and web-based CBT using IBS-specific protocols reduced anxiety and 
depression scores at all follow-up points. [86] These data suggest that treatment with IBS-
specific CBT protocols may benefit both mental health and gastrointestinal symptoms.  
The network meta-analysis suggested that therapist-delivered CBT over the telephone 
had a larger effect on IBS symptoms at follow-up than web-based CBT. [156] However, in 
the ACTIB trial, health economic analysis suggested web-based CBT was the more cost-
effective option. [244] In this trial, the web-based intervention used the same protocol as the 
therapist-delivered CBT over the telephone, [244] but the eight sessions were delivered on an 
interactive, tailored, website. Patients worked through this on their own at home, with guided 
telephone support from the therapist. The network meta-analysis also demonstrated that 
therapist-delivered CBT over the telephone, web-based CBT, face-to-face CBT, and self-
administered or minimal contact CBT were all superior to treatment as usual after 12 months 
of follow-up (Supplementary Figure 22). [156] It is likely that these approaches have similar 
efficacy, but more work is needed to determine cost-effectiveness of the various modes of 
delivery. One advantage of web-based therapies is that they are easy to standardise at scale 
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and monitor usage. However, the disadvantage is that they tend to have lower adherence. [86, 
244]  
Evidence suggests, therefore, that CBT for IBS is effective in both high intensity 
(therapist-delivered) and minimal contact (therapist-guided) formats, as well as self-
administered with either bibliographic material or web-based. There is also some evidence for 
group CBT, but more trials are needed to confirm this. As the ACTIB trial suggested a bigger 
treatment effect with therapist-delivered treatment, but that this was less likely to be cost-
effective, [244] a stepped care approach may provide greatest benefit, where patients with 
more complex needs receive face-to-face CBT, and those with milder symptoms are offered 
web-based or other guided, supported versions.  
Despite an evidence base for use, [156] many psychological therapies are not widely 
available, despite being recommended in the NICE guideline for patients with on-going 
symptoms after 12 months of drug treatment. [10] However, with the success of the ACTIB 
and IBSOS trials, [86, 243, 244] there have been improved training opportunities for 
therapists, and therapist manuals made freely available to Improving Access to Psychological 
Therapy (IAPT) services in the UK, upon completion of a specified training programme. 
Telephone and web-based delivery of CBT also has the potential to further increase access. 
[86] The IAPT service has, therefore, increased its remit to include CBT for IBS, and patients 
can be referred via primary care physicians or can self-refer. More work is needed to enhance 
and standardise the training programme providers to ensure IAPT expertise in this area. 
Therapists without specific IBS training tend to default to using mental health treatments, 
which can disengage patients with IBS. Therefore, referrals should specify that this is for 
IBS-specific CBT.  
Gut-directed hypnotherapy is one of the psychological therapies for IBS with the 
largest evidence base for both short and long-term efficacy in RCTs. [156] The aims of this 
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are to induce a deep state of relaxation in order to teach the patient new skills for self-
management and control of their gut function. [245] The treatment is delivered using IBS-
specific protocols, [245, 246] which incorporate combinations of a variety of techniques 
including imagery, metaphors, tactile approaches to alleviate pain, and diaphragmatic 
breathing specifically targeting abdominal bloating and distension. One of the strengths of the 
treatment is that the content can be tailored according to the patient’s symptom profile. 
Although the exact mechanisms of its effects in IBS remain uncertain, hypnotherapy 
modulates the gut-brain axis, with several studies demonstrating positive changes in gut-brain 
function before, and immediately after, hypnotherapy, including modulation of post-prandial 
gastro-colic reflex activity, [247] altered colonic motility, [248] reduced visceral 
hypersensitivity, [249] and normalisation of gut-brain pain processing signals on functional 
brain imaging. [250, 251]  
Traditionally, hypnotherapy for IBS has been delivered via between 6 and 12 face-to-
face weekly sessions of individualised treatment with a trained therapist. This approach has 
been shown to be efficacious; a meta-analysis of six RCTs, recruiting 639 patients, reported a 
RR of remaining symptomatic of 0.73 (95% CI 0.55 to 0.97) compared with education and/or 
support and 0.67 (95% CI 0.49 to 0.91) compared with a waiting list control (Supplementary 
Figure 20). [156] Moreover, in the largest clinical series to date, including 1000 patients, 
>75% of patients achieved a clinical response to hypnotherapy, defined as a ≥50-point 
reduction in IBS symptom severity score. There were also significant improvements in extra-
intestinal symptoms, and anxiety and depression scores. [252] Hypnotherapy has previously 
only been recommended for patients with IBS when symptoms are refractory to conventional 
treatments. [10] Indeed, a meta-analysis of RCTs has shown that gut-directed hypnotherapy is 
one of the few treatments that performs better than a control for patients with refractory 
symptoms (Supplementary Figure 21). [156] However, its clinical efficacy has also been 
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demonstrated in non-refractory populations, [156] and clinical outcomes in children and 
adolescents with IBS suggest that use of gut-directed hypnotherapy at an earlier stage of the 
condition may be beneficial. [253]  
One of the barriers to wider scale provision of gut-directed hypnotherapy, and its 
current restriction to refractory cases, may be the cost of its delivery, including time intensity, 
and the requirement for a trained therapist. However, intervention with gut-focused 
hypnotherapy has been shown to have wider socio-economic benefits including improving 
general well-being, reductions in healthcare utilisation in both primary and secondary care, 
[254-256] reduced presenteeism at work, [255] improved quality of life, [252, 257] and long-
term beneficial effects on symptoms, [256] making it a potentially cost-effective option. 
Patients with IBS in tertiary care with severe functional limitations may require 
individualised hypnotherapy, with the content of sessions customised to their symptom 
profiles. However, patients in primary or secondary care may benefit from accessing a more 
'generic' form of group-delivered hypnotherapy. In a large, multicentre, RCT in patients with 
IBS in primary or secondary care, group hypnotherapy was shown to be non-inferior to 
individual hypnotherapy. [258] Group hypnotherapy may therefore have a role in primary and 
secondary care settings, with the potential advantage that this approach could reduce delivery 
costs and improve access. Early reports of clinical outcomes via video-consultation are also 
promising, with similar response rates achieved, compared with face-to-face treatment. [259] 
The offer of psychological therapies should not be limited to patients with 
psychological co-morbidities. IBS symptoms are inherently distressing so there are often 
symptoms of anxiety and depression in IBS, but these are not necessarily at case level for a 
psychiatric diagnosis. Nevertheless, it may be worthwhile screening for evidence of both in 
the clinic, using a simple questionnaire, such as the General Anxiety Disorder assessment-7 
and the Patient Health Questionnaire-9, and discussing referral to a mental health service or 
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psychiatrist if mood is felt to be the key issue. The majority of the trials of psychological 
therapies conducted to date include a wide range of IBS patients, many of whom would also 
not have met the threshold for a psychiatric disorder. In contrast to psychological treatments 
used for psychiatric disorders, which focus on mood, the IBS-specific therapies discussed 
here focus on brain-gut symptom-specific treatment mechanisms. The primary aim of 
treatment is to reduce severity and impact of abdominal pain and to help regulate bowel habit. 
They should, therefore, be viewed as behavioural methods for managing and treating IBS 
symptoms, rather than as psychotherapies.  
 
Recommendations 
• IBS-specific cognitive behavioural therapy may be an efficacious treatment for global 
symptoms in IBS (recommendation: strong, quality of evidence: low). 
• Gut-directed hypnotherapy may be an efficacious treatment for global symptoms in 
IBS (recommendation: strong, quality of evidence: low).  
• Psychological therapies should be considered when symptoms have not improved 
after 12 months of drug treatment. Referral can be made at an earlier stage, if 
accessible locally, and based upon patient preference (recommendation: strong, 
quality of evidence: low). 
 
Approach to the Patient with Severe or Refractory Symptoms 
Severe IBS lacks a precise consensus definition, but is considered to be a 
biopsychosocial composite of patient-reported gastrointestinal and extra-intestinal symptoms, 
degree of disability, illness-related perceptions and behaviours, [260] insufficient response to 
conventional treatments, [261] and high health care utilisation. [262] Refractory IBS is a 
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related, but distinct term, again with no consensus definition, which is taken to mean patients 
whose symptoms have not improved with interventions, some of whom may also have severe 
symptoms. Validated severity scoring systems to assess impact and severity of IBS symptoms 
include the IBS severity scoring system, [263] the gastrointestinal symptom rating scale-IBS, 
[264] and the functional bowel disorder severity index. [265] In one European study, 
approximately one in four individuals with IBS were categorised as severe in a general 
population setting. [266] 
Although the risk of missing, or subsequently developing, an organic disorder in 
patients diagnosed with IBS is low, this rate may be increased in those with severe symptoms, 
[267] and should prompt a review of the diagnosis, with consideration of further targeted 
investigation. Nevertheless, it is important to stress that in most patients a diagnosis of IBS is 
secure, [111] and further repeated investigations have a low yield. [268] Severe IBS should 
also be distinguished from other severe functional gastrointestinal disorders that may have 
overlapping symptom presentations, including the narcotic bowel syndrome, if the patient is 
taking long-term opioids, centrally-mediated abdominal pain syndrome, [269] and small 
intestinal dysmotility. [270] Referral to a multi-disciplinary chronic pain team to aid pain 
management and help with opioid reduction should be considered if abdominal pain becomes 
centrally-mediated or if narcotic bowel syndrome develops. 
A large and diverse range of dietary, microbial, traumatic, interpersonal, genetic, 
psychological, physiological, psychiatric, and functional co-morbidity factors have been 
described in patients with severe IBS. [75, 189, 271-276] Consequently, it is unlikely that a 
single targeted intervention will be transformative and a multi-dimensional, multi-system, 
and integrated multi-disciplinary team approach is usually required. Although there is a 
limited evidence base to guide management of this group of patients, as most RCTs do not 
differentiate response to treatment according to baseline symptom severity, there is recent 
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trial data reporting superior outcomes with an integrated approach involving 
gastroenterologists, dieticians, and clinical psychologists, rather than a gastroenterologist 
alone. [277] There is a danger that, in this vacuum, “alternative” therapies with the least 
evidence for their efficacy and safety are recommended by physicians or other practitioners, 
or are sought out by patients. [278]  
Patients with IBS with severe symptoms are more willing to accept significant 
medication risks, for example a mean 1% chance of sudden death in return for a 99% chance 
of cure of their symptoms with a hypothetical medication. [279] Furthermore, patients are at 
increased risk of iatrogenic harms, through unnecessary surgery, including hysterectomy, 
appendicectomy, and cholecystectomy, [121] and inappropriate prescribing of opioids. [90] 
The first principle of care for this vulnerable population of patients should therefore be 
primum non-nocere – first do no harm. This includes harm from unregulated and unproven 
approaches, especially if incentivised by financial or reputational gain. 
Interventions with reported efficacy for patients with undifferentiated IBS specifically 
classified as severe or refractory include CBT, integrative group therapy, gut-directed 
hypnotherapy, gut-brain neuromodulators, or psychodynamic interpersonal therapy. [86, 243, 
252, 280-282] For severe or refractory IBS-C, surgical management, consisting of a 
potentially reversible temporary loop ileostomy, with a view to colectomy if stoma function 
results in improved, rather than worsened, quality of life for the appropriately screened 
patient, [139] the ileal bile acid transporter inhibitor elobixibat, [283] or linaclotide, [284] all 
have some evidential support. For severe or refractory IBS-D, alosetron has regulatory 
approval in the USA for women. [285] In the UK a reasonable alternative might be 
ondansetron although, to date, this has not yet been confirmed to be efficacious in severe or 
refractory IBS. For severe or refractory abdominal pain one study reported efficacy with 
intramuscular hyoscine. [286] 
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Other IBS guidelines suggest the use of combination gut-brain neuromodulators, 
termed augmentation, for more severe symptoms. [226] Evidence from a large cohort of 
patients with severe chronic continuous abdominal pain showed that combinations of 
neuropathic analgesics (e.g., duloxetine plus gabapentin) were more efficacious than 
monotherapy. [287] Vigilance for the development of the serotonin syndrome for some 
combinations, especially those involving both SSRIs and SNRIs, is required. Symptoms 
include pyrexia, hyperreflexia, tremor, sweating, and diarrhoea. For patients with symptoms 
that are refractory to these pharmacological therapies, and those who have co-morbid 
conditions or psychological symptoms, a combination of a gut-brain neuromodulator and 
psychological therapy may be more efficacious than monotherapy with either, drawing 
parallels with evidence from the depression and chronic headache literature. [288, 289] 
 
Recommendations 
• Severe or refractory IBS symptoms should prompt a review of the diagnosis, with 
consideration of further targeted investigation (recommendation: weak, evidence: 
very low). 
• Severe or refractory IBS should be managed with an integrated multi-disciplinary 
approach (recommendation: weak, evidence: very low). 
• Iatrogenic harms due to opioid prescribing, unnecessary surgery, and unproven 
unregulated diagnostic or therapeutic approaches incentivised by financial or 
reputational gain should be avoided (recommendation: strong, evidence: very low). 
• Use of combination gut-brain neuromodulators, termed augmentation, may be 
considered for more severe symptoms, with vigilance for risks of serotonin syndrome 
(recommendation: weak, evidence: very low). 
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Drugs in Development 
The highly selective 5-HT4 agonist minesapride has been studied in two phase-2 dose-
ranging RCTs in patients with IBS-C. [179, 180] A dose of 40mg o.d. was superior to 
placebo, in terms of improvements in number of bowel movements per week, abdominal 
pain, and global symptoms. The drug was well-tolerated, with diarrhoea the most common 
side effect, and there were no cardiovascular adverse events. Histamine has a potential role in 
mediating visceral hypersensitivity, and in a small RCT in 45 patients the histamine-1 
receptor antagonist ebastine led to significant improvements in both abdominal pain and 
global symptoms. [290] A larger trial in 200 patients is on-going (NCT01908465). Novel 
drugs that have been tested successfully in chronic idiopathic constipation, including 
elobixibat and mizagliflozin, a sodium-glucose cotransporter-1 inhibitor, are likely to undergo 
testing in IBS-C. [283, 291] Some secretagogues, including linaclotide, stimulate cyclic GMP 
production, which can attenuate visceral pain. [292] An RCT of delayed-release linaclotide, 
with action confined to the ileo-caecal region of the gastrointestinal tract, demonstrated 
significant effects on abdominal pain, with lower rates of diarrhoea than convention-release 
linaclotide. [165] Other novel approaches include drugs that act on cannabinoid receptors, 
which are expressed in the gastrointestinal tract and may also modulate pain expression. The 
cannabinoid type-2 receptor agonist, olorinab, has been tested in patients with quiescent 
Crohn’s disease, and led to reductions in abdominal pain and improved bowel movements; 
[293] a trial in IBS is underway (NCT04043455). 
 
Other Treatments in Development 
In recent years there has been considerable interest in the evaluation of faecal 
microbiota transplantation (FMT) for IBS. Unfortunately, a meta-analysis of five RCTs, 
containing 267 patients, demonstrated no significant benefit of FMT compared with placebo 
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(RR = 0.98; 95% CI 0.58 to 1.66), and in two pooled trials placebo capsules administered 
orally were superior to capsules containing donor stool (RR = 1.96; 95% CI 1.19 to 3.20). 
[294] Criticisms of the trials, to date, have included small sample sizes, heterogeneity in IBS 
subtypes recruited, lack of standardisation of donor samples, and suboptimal endpoints used. 
There is therefore a need for further, large, high-quality trials of FMT for IBS, perhaps 
targeting sub-groups of patients with evidence of dysbiosis, who may be more likely to 
benefit. At present, therefore, there is insufficient evidence to recommend FMT for IBS 
outside of a research setting. Enterosgel, an intestinal adsorbent approved for use in IBS-D 
and available over-the-counter in the UK is currently the subject of a multi-centre RCT in 
IBS-D. [295] For IBS-C, there are ongoing trials of an exo-peristalsis device. [296] Future 
research priorities are outlined below. 
 
RESEARCH: BARRIERS, PRIORITIES, AND IMPLICATIONS FOR FUTURE 
STUDY DESIGN  
Current treatments for IBS are often inadequate and many patients remain unsatisfied 
with medical care. [91, 92, 95] Despite this, and the high prevalence of IBS, the pipeline of 
new treatments is relatively poor. This is related to several factors, including the challenges of 
running large RCTs, high thresholds for licensing of therapies, and relatively low levels of 
academic funding, as IBS is not viewed as a priority by funders. [297] The negligible 
mortality associated with IBS, [149] together with the association with common mental 
disorders, [119] and the stigmatisation of the condition, [106, 107] likely contribute to the 
latter. More research is required to understand the burden of suffering of IBS patients and the 
direct consequences to daily life. With such a prevalent condition, it should be relatively 
straightforward to recruit to large RCTs, but these have often recruited slowly, and sometimes 
failed. This leads to a waste of both resources and participant time invested. The consequent 
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failure to evaluate treatment efficacy adequately limits availability of potentially useful 
therapies.  
These failings also have indirect effects, leading to reduced confidence of funders and 
sponsors, making trials of other therapies more challenging. There are three critical reasons 
for difficulty recruiting to IBS trials. Firstly, highly restrictive inclusion criteria reduce the 
eligible population. Among individuals who believe themselves to have IBS, only around 
60% fulfil Rome IV criteria, whereas 80% fulfil Rome III. [23] There are often severity 
criteria built in, which aim to exclude the most severe or refractory symptoms, as well as less 
severe cases. In addition, many treatments are restricted to patients with IBS-C or IBS-D, 
whereas those with IBS-M or IBS-U are rarely recruited; indeed, although there are 
established composite endpoints for IBS-C and IBS-D, these do not exist for IBS-M or IBS-
U. Secondly, recruitment to trials is optimal when patients are linked to specialist clinics. 
However, patients with IBS are widely disseminated, mostly in community care, often with 
no long-term follow-up, and only a minority attend specialist clinics where research is 
undertaken. This latter group is often more complex, more refractory and, by definition, less 
appropriate for treatment trials. Thirdly, patient and public involvement exercises have 
identified that trial protocols are onerous and unrealistic. There are often too many visits, a 
need for invasive investigations, and a high burden of data collection. Patients who enter IBS 
trials have usually tried all available treatments and remain unsatisfied with care, so being 
randomised to “standard care” for ≥12 weeks is unappealing.  
Future trial design needs to take these issues into consideration, using a pragmatic and 
participant-focused approach. Inclusion criteria should be consistent with the population that 
will receive the treatment. If studying a safe over the counter treatment, restricting inclusion 
to only those meeting Rome IV criteria is questionable. As with our recommendations for 
diagnosis, emphasising a more pragmatic clinical definition of IBS, together with limited 
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need for investigations, the same principles should apply to trial eligibility. This would allow 
faster recruitment to RCTs, provide equity of access for patients, and give a better indication 
of the true benefit of treatments being studied in the population most likely to use them. 
Trials should include an open-label phase, wherever possible, to allow access to the active 
treatment for all participants, with data collection limited to that necessary to prove efficacy 
and avoid use of multiple secondary academic objectives. 
Recruitment methods need to include community-based approaches, involving 
primary care settings, social media campaigns, and consent-for-contact registries. The 
geographical exclusion produced by site-dependent recruitment can be overcome by a remote 
access, or virtual, approach. [298] IBS research is leading the way in this regard with the first 
UK interventional virtual trial being conducted in IBS, demonstrating that virtual recruitment 
methods out-perform site-dependent recruitment significantly. [295, 299] Although RCTs 
remain the gold standard, they have many weaknesses, and modern methods of trial design 
may be more suitable to studying IBS. The use of virtual controls, artificial intelligence, and 
big data solutions, together with meaningful real-time outcome data should be considered. 
Some important areas of research are listed below, but this is not exhaustive, will change over 
time, and needs to be informed by a priority-setting partnership. 
 
Recommendations 
• Successful completion of large clinical trials will require pragmatic inclusion criteria, 
minimisation of the participant trial burden, and effective recruitment strategies that 
reach into community settings. Virtual (remote access) trial approaches will reduce 
geographical exclusion. 
• A priority-setting partnership would best discern valuable research questions. 
• Some future research themes include, but are not limited to: 
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Characterisation of the illness to understand predictors (clinical, genetic, 
psychological, and biological) of outcome and treatment response, 
determinants of refractory illness, and burden of illness (particularly with 
respect to workplace productivity) by conducting large-scale epidemiological 
studies with extended observation. 
Trials of novel treatments, including pharmacological, dietary, and 
behavioural therapies, device-based treatments, and faecal microbiota 
transplantation. There is also a need for development of visceral analgesics. 
Consideration should be given to stratifying randomised controlled trials by 
IBS severity and subtype, burden of extra-intestinal symptoms, and 
psychological co-morbidity.  
A better understanding of treatment combinations to uncover augmentation 
effects between therapies, and to assess the value of multi-disciplinary 
approaches. 
Modulation of pain and psychological responses using pharmacological (e.g., 
serotonin norepinephrine reuptake inhibitors) or behavioural approaches (e.g., 
cognitive behavioural therapy used earlier in the disease course or via digital 
provision), and comparison of cognitive behavioural therapy with gut-directed 
hypnotherapy. 
Med-tech approaches (web-based, apps, and devices) to behavioural 
modification. 
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CONCLUSIONS 
This guideline has summarised current evidence regarding the diagnosis and 
management of IBS and is intended to be a practical guide for clinicians seeing patients with 
the condition. IBS is a multi-factorial disorder of gut-brain interaction, and the evidence 
summarised here underlines the importance of effective communication, making a positive 
diagnosis, and instituting appropriate, evidence-based non-pharmacological and 
pharmacological therapies according to predominant symptoms, global patient assessment, 
and patient choice, in order to improve both symptoms and quality of life within a bio-
psychosocial framework. This guideline has also highlighted emerging new therapeutic 
options for IBS and priority areas for on-going research.  
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Table 1. The Rome IV Criteria for Irritable Bowel Syndrome. [2] 
Rome IV IBS Diagnostic Criteria 
1. Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months and associated with two 
or more or the following: 
a. Related to defaecation; 
b. Associated with a change in frequency of stool; 
c. Associated with a change in stool form. 
AND 
2. Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis 
IBS-C IBS-D IBS-M IBS-U 
≥25% of bowel 
movements of Bristol 
stool form types 1 or 2, 
and <25% of Bristol 
stool form types 6 or 7. 
≥25% of bowel 
movements of Bristol 
stool form types 6 or 7, 
and <25% of Bristol 
stool form types 1 or 2. 
≥25% of bowel 
movements of Bristol 
stool form types 1 or 2, 
and ≥25% of bowel 
movements of Bristol 
stool form types 6 or 7. 
Patients who meet 
criteria for IBS, but who 
do not fall into one of the 
other three sub-groups 
according to Bristol stool 
form type. 
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Table 2. Lower Gastrointestinal Alarm Symptoms or Signs That Are Referral Criteria 
for Suspected Colorectal Cancer. [84] 
Definite Referral Criteria 
Aged ≥40 years with unexplained weight loss and abdominal pain. 
Aged ≥50 years with unexplained rectal bleeding. 
Aged ≥60 years with: 
a. Iron deficiency anaemia; or 
b. Change in bowel habit 
Positive faecal occult blood test 
Probable Referral Criteria 
Adults of any age with an abdominal or rectal mass 
Aged <50 years with rectal bleeding and any of the following unexplained symptoms or findings: 
a. Abdominal pain; 
b. Change in bowel habit; 
c. Weight loss; or 
d. Iron deficiency anaemia. 
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Figure 1. Diagnostic Algorithm Detailing the Approach to the Positive Diagnosis of 
Irritable Bowel Syndrome.  
*If the initial faecal calprotectin level is abnormal (e.g., >250mcg/g) the suspicion for IBD is 
high, proceed to colonoscopy; if the initial faecal calprotectin level is indeterminate 
according to local laboratory values (e.g., 100-249mcg/g), repeat the test off non-steroidal 
anti-inflammatory drugs, proton pump inhibitors, etc., and refer for colonoscopy if the repeat 
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Figure 2. Treatment Algorithm for Irritable Bowel Syndrome.  
*Review efficacy after 3 months of treatment and discontinue if no response. 
†As per NICE IBS dietary advice sheet, plus consider ispaghula. 
‡Tricyclic antidepressants should be first choice, starting at a dose of 10mg at night, and 
titrating slowly (e.g., by 10mg per week) according to response and tolerability. Continue for 
at least 6 months if the patient reports symptomatic response. 
±Where available locally, and based on patient preference, psychological therapies can be 
considered at an earlier stage, but are recommended strongly when symptoms are refractory 
to drug treatment for 12 months. 
 
